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ABSTRACT 
 
 
 
A NEW APPROACH TO DRIED BLOOD SPOT ANALYSIS FOR NEWBORN SCREENING USING HIGH 
RESOLUTION LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY 
 
By John H. Miller IV, B.S. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2012 
 
Major Director: H. Thomas Karnes, Ph.D. Professor Department of Pharmaceutics, School of 
Pharmacy 
 
The primary purpose of newborn screening is to quickly identify children that are at risk 
of having a specific disorder in order to start treatment, prevent early death and reduce the 
chances of permanent physical or mental damage.  The current and widely accepted approach 
used for identification of metabolism disorders involves a flow injection analysis with mass 
spectrometry detection of acylcarnitines and amino acids.  Although this approach is widely 
accepted and has shown to be sufficient for identification of multiple metabolism disorders the 
method is not fully quantitative and results often have to be confirmed by second-tier tests.   
The primary focus of this research was to improve the accuracy and selectivity of this 
screening method by employing a high resolution chromatographic separation for the 
combined analysis of twelve acylcarnitines and seven amino acids.   This method is an 
improvement over the current methodology allowing for separation of key isomers that are 
diagnostic for different metabolism disorders, reducing the need for multiple second-tier tests 
to confirm results and shortening the time to diagnosis.  
 xv 
 In order to further improve the efficiency of newborn screening we developed an in-
line desorption device, which allows for direct analysis of DBS eliminating the need for punching 
disks from the filter paper cards.  Our device was the first published paper that demonstrated 
the ability to directly analyze dried blood spots, without the need for any offline sample 
processing.  Using this device, we validated a method to quantify biomarkers related to Maple 
Syrup Urine Disease, a disorder that requires a second-tier test for confirmation.  
To further improve the accuracy of dried blood spot analysis we evaluated a technique 
to correct the sample volume in low and high hematocrit samples.  The level of hematocrit in 
blood spotted on filter paper cards affects the volume of sample analyzed, leading to errors in 
accuracy.   Diffuse reflectance was used to relate differences in sample hematocrit on dried 
blood spots.  We validated our technique with eighteen donor samples at various levels of 
hematocrit.  Correcting sample volume for hematocrit showed improved precision and accuracy 
over the standard approach, ultimately reducing the potential to misidentify samples.     
 
 1 
CHAPTER 1 
 
BACKGROUND TO NEWBORN SCREENING DRIED BLOOD SPOT 
ANALYSIS 
 
 
1.1  Introduction 
1.1.1  Background to newborn screening  
Since the late 1960’s it has been a requirement that all state laboratories screen 
newborns for inherited metabolism disorders (Sahai & Marsden, 2009).  Initially, the state 
laboratories screened for just one disorder, phenylketonuria (PKU), but gradually additional 
tests were added to the screening panel as they were identified.  The primary purpose of 
implementing newborn screening testing was to quickly identify children that were at risk of 
having a specific disorder in order to start treatment, prevent early death and reduce the 
chances of permanent physical or mental damage.  The cost of screening every newborn was 
justified by the ability to save lives by early diagnosis and treatment versus the expenses 
associated with long term health effects of untreated babies (Millington, 2005).  Current 
screening methods are able to identify as many as 40 different disorders from a single sample 
(Chace, Kalas, & Naylor, 2003; Sweetman, 2001).  Blood is collected from each newborn within 
the first week of life using the same technique developed for the analysis of PKU by Robert 
Guthrie (Guthrie & Susi, 1963).  The newborn’s heel is pricked and the blood is spotted on filter 
paper cards, allowed to dry and sent to state laboratories for testing.  Several different tests are 
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performed on each sample; some tests require separate analysis for identification of specific 
disorders.   Acylcarnitines and amino acids, markers for a variety of metabolism disorders, are 
typically screened in a single analysis employing flow injection with mass spectrometry 
detection.  
  Acylcarnitines are diagnostic markers for both fatty acid oxidation defects and organic 
acid disorders.  Carnitine (C0) plays an essential role in the transport of fatty acids to the 
mitochondrial for the production of energy (Sahai & Marsden, 2009).  The acylcarnitine 
nomenclature is based on the chain length of the fatty acid attached to C0, for example a C6 is 
the base carnitine attached to a six carbon fatty acid.  Structures with unsaturated fatty acid are 
identified as C6:1 where the 1 indicates a single unsaturated bond.  Dicarboxylic fatty acids and 
hydroxylated fatty acid species are represented by “-DC” and “-OH” respectively.  The 
formation of an acylcarnitine is show in Figure 1.1. where “R” represents the long chain fatty 
acid that binds with C0. 
 
H3C
N+
H2
C
CH
H2
C O
OOHCH3
H3C
H
OH
CO
R
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H2
C
CH
H2
C O
OOCH3
H3C
H
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R
+
Carnitine (C0) Acylcarnitine
Fatty Acid
  
Figure 1.1: Reaction of free carnitine with a fatty acid to produce an acylcarnitine 
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When there is a deficiency in an enzyme specific to the metabolism of fatty acids, it 
results in an increase in blood levels of acylcarnitines (Sahai & Marsden, 2009).  Since the 
enzymes are selective based on the chain length, the enzyme responsible for a disorder can be 
identified based on elevation of specific acylcarnitines.  Elevated levels of C6, C8 and C10 are an 
indication of medium chain acyl CoA dehydrogenase deficiency (MCAD) (Sahai & Marsden, 
2009).  Elevated C16-OH, C16 and C18:1-OH are an indication long-chain L-hydroxyacyl-CoA 
dehydrogenase deficiency (LCHAD), and elevated C14, C14:1 and C16 are indications of very 
long chain acyl-CoA dehydrogenase deficiency (VLCAD) (Sahai & Marsden, 2009).  
Organic acid disorders arise from impairment of enzymes responsible for the breakdown 
of amino acids prior to the citric acid cycle (Sahai & Marsden, 2009).  As a consequence excess 
levels of short chain organic acids are formed and conjugate with carnitine.  Several organic 
acid disorders involving vitamin B12 result in elevated levels of Propionylcarnitine (C3) (Sahai & 
Marsden, 2009).  Other enzyme deficiencies in the metabolism of amino acids will result in 
elevated levels of specific amino acids. Phenylketonuria (PKU) is a classical amino acid disorder 
in which there is a deficiency in the enzyme responsible for the metabolism of phenylalanine 
(Sahai & Marsden, 2009).  This results in abnormally high levels of phenylalanine, which can 
cause mental retardation if untreated.   
Newborn screening methods typically screen for six to eleven amino acids and nine to 
twenty acylcarnitines. Positive samples are flagged for clinical diagnosis, in which an 
experienced clinician analyzes the mass spectral data and starts an intervention process with 
the primary care physician and parents.  Diagnosis for a specific disorder requires testing of 
 4 
additional blood and urine samples using a quantitative technique and chromatographically 
separates the analytes by either gas chromatography or high performance liquid 
chromatography.  Additional markers are analyzed, such as urinary organic acids, for clinical 
diagnosis of certain disorders.  Clinical diagnoses tests are typically conducted by independent 
laboratories which results in additional time and expense to determine the health of the child.  
Once the child is identified as having a specific disorder, the exact nature of the deficiency is 
evaluated by testing the level of enzyme activity or gene sequencing.  A typical test for enzyme 
activity requires profiling the metabolism of a specific analyte in the presence of an enzyme 
(Wolf, Grier, Allen, Goodman, & Kien, 1983).  Although there are some colorimetric tests that 
can be employed at newborn screening centers they are not fully quantitative and often have 
to be confirmed by a second laboratory.  Gene sequencing is more complex and requires a 
second sample to be taken from the newborn (Tiranti et al., 2004). The samples are usually 
analyzed using a Western Blot approach along with gel electrophoresis to identify specific 
differences in the genome.   
1.1.2  Current methodology 
There are two widely used approaches in newborn screening for acylcarnitines and 
amino acids.  The original and widely accepted method requires the analytes to be derivatized 
prior to analysis and a more recent approach does not require derivatization.  Both techniques 
allow for identification of several different metabolism disorders in a single analysis.  The 
original technique used by most state laboratories was developed at Duke University and 
involves the derivatization of the carboxylic acid functional group with n-butanol and 
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hydrochloric acid to form butyl esters (Millington, Kodo, Norwood, & Roe, 1990).  The final 
extracts are analyzed by flow injection analysis (Figure 1.2).  Flow injection implies that the 
sample is injected without chromatographic separation; instead, the sample is injected into the 
flow path of the mobile phase, which carries the plug of sample to the mass spectrometer.  The 
flow rate is reduced prior to the sample reaching the mass spectrometer which improves the 
sensitivity of the method by broadening the elution plug so that the signal can be averaged over 
a longer time period.  Flow injection analysis can be done rapidly in 2-5 minutes, allowing for 
hundreds of samples to be analyzed in a single day (Sweetman, 2001). 
Figure 1.2: Flow injection analysis for an extracted dried blood spot sample derivatized with 
n-butanol with insert showing the mass spectra for acylcarnitines analyzed by precursor ion 
scan for the production of 85 m/z  
N
or
m
al
iz
ed
 R
es
po
ns
e 
Precursor Ion Scan m/z 85 
N
or
m
al
ize
d 
Re
sp
on
se
 
 6 
The mass spectral analysis can be very complex; however, most laboratories use 
specialized software to help identify and quantify the analytes of interest.  Also, there is no 
separation between the analytes and matrix components which could affect the quantitation of 
some analytes, especially for compounds that do not have labeled internal standards.  For 
analysis of butylated acylcarnitines, the mass spectral data is collected for positive precursor 
ions of the 85 m/z production.  Under these conditions the mass spectrometer allows all ions to 
pass through the first quadrupole and into the collision cell.  The ions are fragmented and only 
ions with 85 m/z pass through the third quadrupole and associated precursor ion from the first 
quadrupole is identified.  The derivatized amino acids are analyzed in a similar fashion, typically 
monitoring the neutral loss of 102 m/z.  A neutral loss scan function only allows specific ions 
that lose a designated mass to pass through to the third quadrupole.  In scan mode the 
instrument has to ramp the voltage applied to the quadrupole in a specified time to filter ions 
from low to high mass to charge (m/z). Although this allows for multiple compounds to be 
detected in a single scan it results in lower sensitivity since the time that the mass spectrometer 
is detecting an individual mass is a fraction of the scan time.  An alternative approach is used to 
improve the sensitivity for difficult to detect compounds is called multiple reaction monitoring 
(MRM).  In this technique the mass spectrometer monitors a specific molecular mass and a 
specific fragment ion in a specified dwell time.  Multiple reaction monitoring provides the best 
sensitivity for an analyte since the mass spectrometer does not need to scan across a series of 
masses.  Figure 1.3 shows a schematic of mass spectrometer and the different scanning modes 
used.  
  
 
Scan Type Q1 Q2 Q3 
Analytes 
Detected 
Parent Ion Scan Scan all masses Fragmentation Only mass with 85 m/z Acylcarnitines 
Neutral Loss Scan all masses Fragmentation Only masses that lost  102 m/z Amino Acids 
MRM Selected molecular  ion mass Fragmentation Selected fragment mass 
Selected Amino 
Acids 
 
Figure 1.3: Schematic of a triple quadrupole mass spectrometer with descriptions of different scan modes used by newborn 
screening for analysis of amino acids and acylcarnitines 
 
 
1st Quadrupole Collision Cell 3rd Quadrupole Detector ESI 
 Source 
Mobile 
Phase 
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1.1.3  Quantification of acylcarnitines and amino acids 
Quantification of amino acids and acylcarnitines is based on the response factors 
determined using isotopically labeled internal standards.   Dried blood spots are extracted in a 
solution containing isotopically labeled internal standards at known concentrations.  In the 
derivatization based screening method the internal standards are also derivatized during the 
sample preparation to form their butyl esters.  The response of the internal standard is used to 
determine the concentration of the analyte based on Equation 1.1 where the response factor is 
either previously determined or assumed to be equal to one.  It is recommended that the 
response factors be determined prior to analysis using Equation 1.2 in order to more accurately 
quantify each analyte.  However, most laboratories set cut-off values independently based on 
response of normal samples and set a cut-off above this range to identify abnormal samples. 
Although, this has been proven to be acceptable for screening there are potential problems 
with using a single point response factor for quantitating samples.  This technique assumes that 
the response of the internal standard is equivalent to the response of the analyte and that the 
analyte and internal standard are equally affected by matrix suppression or enhancement, 
however this is not always true (Trufelli et al., 2011).   
 
Equation 1.1: Conventional calculation for concentration for analytes extracted from dried 
blood spots 
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Equation 1.2: Response factor determination for external solutions 
 
1.1.4  Issues associated with newborn screening 
Although there are several advantages to using this method for screening, there are also 
several inherent problems.  The method primarily used but most state laboratories require 
multiple extraction steps including derivatization and multiple evaporation steps.  
Derivatization has been employed to improve sensitivity of some compounds, but there are 
issues as to the efficiency of the derivatization for others (Sapp et al., 2007).  Hydrochloric acid 
used in the derivatization step is caustic, hazardous and destroys laboratory equipment with 
prolonged exposure.  Even though the flow injection analysis allows for hundreds of samples to 
be analyzed in a single day, it lacks the selectivity to differentiate between disorders associated 
with isobaric analytes.  The screening method is not fully quantitative and relies on individual 
laboratory cut-off values to determine test positive samples.  Another concern is the volume of 
sample analyzed has been shown to be affected by differences in hematocrit (Mei et al., 2001).  
Hematocrit affects the diffusion properties of blood on the filter paper.  Samples with high 
hematocrit will not diffuse as much as samples with low hematocrit.  Since newborn screening 
uses a predefined punch size to analyze samples (either 3.0 mm or 6.0 mm) the actual volume 
will vary depending on hematocrit.  It has been previously shown that samples with abnormally 
low or high hematocrit have dramatic differences in sample volume which could result in the 
misidentification of disorders (Mei et al., 2001).   
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A major drawback to flow injection analysis is the lack of separation of isobars; 
compounds having the same mass but are structurally different.  In some cases the different 
isobars are diagnostic for separate disorders, and clinical diagnosis is required for proper 
identification of a disorder (Bennett, 2009; Sweetman, 2001).  Leucine, isoleucine, and 
hydroxyproline all have the same molecular ion 131 m/z and appear as a single entity in 
newborn screening tests.  Although leucine and isoleucine are both used as indicators for maple 
syrup urine disease (MSUD) their response factors are different and elevated levels of one 
isomer can influence the screening result (Chace et al., 1995).   In addition, a variation in 
hydroxyproline levels can lead to inaccurate diagnosis of MSUD (Matern, Tortorelli, Oglesbee, 
Gavrilov, & Rinaldo, 2007).  There are also several acylcarntines that have the same mass, C4-
isomers  butyrylcarnitine and isobutrylcarnitine are symptomatic of two different disorders; 
short-chain acyl-CoA dehydrogenase (SCAD) and isobutryrl-CoA dehydrogenase deficiency 
respectively (Chace et al., 2003).  C5-isomers valerylcarnitine and isovalerylcarnitine appear at 
245 m/z and other species such as 3-hydroxyisovaleryl carnitine, 2-methyl-3-hydroxybutyryl 
carnitine and butyrylcarnitine dicarboxylic acid (C4DC) appear at 262 m/z. These species are 
indicators of specific disorders, but are not separated using flow injection analysis and require 
additional testing for confirmation of the disorder.  All final diagnostic tests for analysis of 
amino acids and acylcarnitines involve some form of chromatographic separation.   
Another issue not previously evaluated in newborn screening is the potential for the 
matrix to affect the quantification of analytes.  Although labeled internal standards are used for 
quantification, the response of the internal standard could be affected differently relative to 
the analyte by other compounds in the matrix (Trufelli et al., 2011).  In addition there is the 
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potential for matrix related components, such as phospholipids, to dramatically reduce the 
ionization of some analytes to an undetectable level.  Since there is no chromatographic 
separation employed in the screening method, all the analytes appear at the same time as the 
other matrix components. Matrix effects can dramatically affect quantification of analytes even 
if labeled internal standards are used and should be evaluated in newborn screening methods 
(Lindegardh, Annerberg, White, & Day, 2008).  The FDA requires bioanalytical methods to be 
evaluated for matrix effects to ensure that quantification is accurate and precise (US FDA. 
Guidance for Industry: Bioanalytical Method Validation, 2001).   
1.1.5  Misdiagnosis of patients  
Established ranges have been determined for each analyte in order to differentiate 
between normal healthy levels and diseased levels.  Due to overlap in these ranges, cut-off 
values have to be set.  However, it has been reported that as many as 20% of babies initially 
identified as having a disorder are later determined to be healthy (Sahai & Marsden, 2009).  
Although, adjusting the cut-off values higher would reduce the number of false positives it 
would also increase the occurrence of false negatives (Sweetman, 2001).  
False positive cases occur when newborns are identified as having a disorder, but after 
additional testing the child is determined to be healthy.  This has less of an impact to the child, 
but it has shown to result in psychological and emotional issues for the parents (la Marca et al., 
2007; Schulze et al., 2003; Sweetman, 2001). It has been reported that less than 27% of 
newborns identified by current screening methods as having methylmalonic acidaemias are 
diagnosed with this disorder after employing a more selective second-tier test (Matern et al., 
2007).  Propionylcarnitine (C3) is the primary marker for methylmalonic acidaemias, however 
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methylmalonic acid has been identified as a more selective marker.  This example demonstrates 
the poor specificity of current markers for some diseases that could be addressed by adding 
more specific markers to the screening method.  Proper diagnosis of MSUD using newborn 
screening methods also has a high false positive rate due to lack of chromatographic separation 
between leucine, isoleucine and hydroxyl proline, as discussed earlier.  Most laboratories have 
implemented second-tier testing for confirmation of disorders that have a high false positive 
rate.  These second-tier tests often involve a second analysis for more specific markers and 
require a chromatographic separation.         
1.1.6  Requirement for second-tier testing  
As discussed above, one of the major issues with the current newborn screening 
method is it is not completely diagnostic, and markers are not always specific to a single 
disorder (Matern et al., 2007; Sweetman, 2001).  Newborn screening laboratories have 
implemented more selective second-tier tests for some disorders to confirm test positive 
samples prior to physician notification (Matern et al., 2007).  Although these second-tier tests 
do provide additional specificity, additional instrumentation and personnel are needed for 
these analysis.  Some laboratories screen for more specific markers such as succinylacetone for 
diagnosis of Tyrosinemia Type 1 (Al-Dirbashi et al., 2008; Matern et al., 2007; Turgeon et al., 
2008).   Several second-tier tests have been published for the diagnosis of elevated C3 which is 
a marker for four potential disorders: methylmalonic academia, cobalamin deficiency, 
homocystinuria and propionic academia (la Marca et al., 2007; Magera, Helgeson, Matern, & 
Rinaldo, 2000; Matern et al., 2007; Weisfeld-Adams et al., 2009).  The current approach to 
second-tier testing is that one second-tier test is employed for each disorder which results in 
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multiple second-tier tests. Having a more comprehensive screening method would eliminate 
the need for multiple second-tier tests, reducing costs and ensuring faster and more accurate 
identification of certain disorders.  To date there is not a comprehensive method that can 
chromatographically separate both acylcarnitines and amino acids in a single analysis that 
would be suitable for screening or as a second-tier test.  
1.2  Chromatographic separation of acylcarnitines and amino acids 
1.2.1  Current methods for acylcarnitines and amino acids 
Analysis of acylcarnitines and amino acids can be very complex due to the nature of 
these analytes.  Amino acids are very polar compounds and are not well retained on 
conventional reverse phase columns such as an octadecyl (C18) phase. This is due to the fact 
that amino acids contain both an acidic and basic functional group and they are ionized under 
most of the typical chromatographic conditions.  This makes amino acids more water soluble 
and therefore they stay in the mobile phase and do not interact with a hydrophobic stationary 
phase.  Acylcarnitines have extremely diverse polarity from carnitine being the most polar to 
stearoylcarnitine (C18) which is very non-polar. The polarity differences between these 
compounds are affected by the hydrophobic carbon chain attached to a portion of the 
molecule.  The length of this chain will affect the hydrophobicity of the molecule, resulting in 
longer retention on a reverse phase column.    Another issue with analysis of both amino acids 
and acylcarnitines is that most of these analytes do not contain a chromophore necessary to 
absorb UV light.  Therefore, these analytes cannot be analyzed by UV or fluorescence 
techniques without some type of derivatization to enhance their detection.  Although there 
have been several published methods for the analysis of amino acids and acylcarnitines, very 
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few methods have included both in the same analysis.  In addition, a rapid screening method 
should be capable of chromatographically resolving all these analytes and isobaric species with 
run time less than 5 minutes  
Published methods for analysis of acylcarnitines employ a variety of chromatographic 
conditions and modes of detection.  As stated previously, analysis of acylcarnitines for UV 
absorbance or fluorescence detection required some form of derivatization.  
Pentafluorophenacyl trifluoromethanesulfonate (Minkler, Ingalls, & Hoppel, 2005) and 2-(2,3-
naphthalimino)ethyl trifluoromethanesulfonate  (Minkler, Kerner, North, & Hoppel, 2005) have 
been used for derivatization of acylcarnitines for UV and fluorescence detection respectively. 
Although these methods are suitable for quantitative analysis of acylcarnitines the analysis 
times are extremely long and they would not be practical for a rapid screening method or for a 
second-tier test.  An alternative approach would be to use electrospray ionization with mass 
spectrometry detection.  However, the current published methods are still not suitable for 
newborn screening due to analysis times that are longer than 10 minutes (Ghoshal, Guo, 
Soukhova, & Soldin, 2005; Maeda et al., 2007), the requirement for alternative instrumentation 
(Chalcraft & Britz-McKibbin, 2009) or that they utilize ion pair reagents (Vernez, Wenk, & 
Krahenbuhl, 2004).  Comprehensive methods for analysis of acylcarnitines, such as dicarboxylic 
acid and hydroxylated species have been reported, however quantification of all these species 
adds additional complexity to the analysis and are not necessary for screening (Maeda et al., 
2008). Others have reported the separation of key isobars such as C4 and C5 which does allow 
for differential diagnosis for short chain acyl-coenzyme A dehydrogenase deficiency (SCAD) and 
isobutyryl-CoA dehydrogenase deficiency (IBCD) or isovaleric academia (IVA) (Forni, Fu, Palmer, 
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& Sweetman, 2010). Recently there was a report for the analysis of 48 acylcarnitines from dried 
blood spots using UHPLC-MS/MS on a C18 column with a 15 minute analysis time (Gucciardi, 
Pirillo, Di Gangi, Naturale, & Giordano, 2012). This method does provide chromatographic 
separation for a comprehensive list of acylcarnitines including several isobars, but the analysis 
time is still not practical for a rapid test.  Table 1.1 provides a comparison of all the published 
methods for acylcarnitine analysis.  
Almost all the reported methods for amino acid analysis involve some form of 
derivatization either pre-column or post-column.  Derivatization is used to enhance the 
retention of these analytes in reverse phase chromatography and to improve the detection by 
UV absorbance or fluorescence.  There are several commercial kits available for this analysis 
including Agilent’s Aminoquant method and Water’s AccQ•Tag™ Ultra derivatization method 
(Armenta et al., 2010).  Although chromatographic separation for amino acids using these 
methods can be achieved in approximately 10 minutes, both of these kits involve additional 
derivatization reagents and specialty columns for the analysis. Kasper recently published a 
review of current methods for the analysis of amino acids in biological samples by HPLC with UV 
or fluorescence detection, ion-pair chromatography, capillary electrophoresis, GC/MS, 
UPLC/MS and 2-dimensional NMR (Kaspar, Dettmer, Gronwald, & Oefner, 2009).  A 
comprehensive list of published methods for the chromatographic separation of amino acids is 
included in Table 1.1.  To date there are no published papers involving the separation of both 
amino acids and acylcarnitines with a run time that would be comparable to the analysis time 
to the newborn screening flow injection technique. 
  
Table 1.1: Comprehensive list of methods for used for analysis of acylcarnitine and amino acid 
Compound 
Class Analytes 
Analysis 
 time Instrumentation Comments Reference 
Acylcarnitines 15 acylcarnitines 70 min HPLC-UV 
Derivatization with 
pentafluorophenacyl 
trifluoromethanesulfonate  
(Minkler et al., 
2005) 
 7 long chain 
acylcarnitines 13 min HPLC-FLD 
Derivatization with 2-(2,3-
naphthalimino)ethyl 
trifluoromethanesulfonate 
(Minkler, Kerner 
et al., 2005) 
 17 acylcarnitines 33 min LC-MS/MS Analysis of Human Serum and Urine 
(Maeda et al., 
2007) 
 17 acylcarnitines 33 min LC-MS/MS Analysis of Human Serum and Urine 
(Maeda et al., 
2008) 
 7 acylcarnitines 
and 13 amino 
acids 
16 min CE-MS/MS 
Requires alternative 
instrumentation and only 
analyzes for select 
acylcarnitines 
(Chalcraft & Britz-
McKibbin, 2009) 
 
10 acylcarnitines 17 min LC-MS/MS 
Poor chromatography for 
several of the acylcarnitines, no 
derivatization required 
(Ghoshal et al., 
2005) 
 
10 acylcarnitines 10 min LC-MS/MS 
Previous method modified from 
17 min to 10 minutes, no 
derivatization required 
(Ghoshal, Balay, & 
Soldin, 2006) 
 
48 acylcarnitines 15 min UPLC-MS/MS 
Most comprehensive method, but 
it does not include quantitative 
analysis of amino acids 
 
(Gucciardi et al., 
2012) 
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Compound 
Class Analytes 
Analysis 
 time Instrumentation Comments Reference 
Acylcarnitines 6 long chain acylcarnitines 12 min LC-MS/MS 
Method not comprehensive and 
used for the analysis of PC-12 
cells 
(Jauregui et al., 
2007) 
Amino Acids 25 amino acids 10 min 
UHPLC-FLD or LC/MS/MS 
Waters AccQ-Tag 
derivatization. 
Requires specialized reagents 
and columns.  Derivatization 
with 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate  
(Armenta et al., 
2010) 
 
15 amino acids 60 min 
HPLC Electrochemical 
Detection 
Derivatization with o-
phthalaldehyde–2-
mercaptoethanol or 
ophthalaldehyde 
 
Requires Derivatization, 
specialized detection and long 
analysis time 
(Tcherkas, 
Kartsova, & 
Krasnova, 2001) 
 
14 amino Acids 60 min 
HPLC FLD 
Derivatization with o-
phtalaldehyde, 2-
mercaptoethanol as 
catalyst 
Not validated for biological 
samples, requires derivatization 
and long analysis time (glues) 
(Peris-Vicente, 
Gimeno 
Adelantado, 
Carbó, Castro, & 
Reig, 2006) 
 
21 amino acids 30 min 
HPLC-FLD 
Derivatization with o-
phtalaldehyde, 2-
mercaptoethanol as 
catalyst 
Not validated for biological 
samples, requires derivatization 
(wine) 
 
 
 
(Soufleros, 
Bouloumpasi, 
Tsarchopoulos, & 
Biliaderis, 2003) 
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Compound 
Class Analytes 
Analysis 
 time Instrumentation Comments Reference 
Amino Acids 23 amino acids 17 min 
HPLC FLD 
OPA derivatization 
Requires derivatization (Fekkes, 1996b) 
 
38 amino acids 115 min 
Ion Exchange  
LC-UV 
Derivatization with 
ninhydrin reagent 
Requires derivatization and 
extremely long analysis time 
(Le Boucher, 
Charret, Coudray-
Lucas, Giboudeau, 
& Cynober, 1997) 
 
16 amino acids 15 min 
Ion Pair LC/MS/MS 
Ion pair reagent: 
nonafluoropentanoic 
acid 
Ion pair chromatography (de Person, 
Chaimbault, & 
Elfakir, 2008) 
 
26 amino acids in 
plasma and 22 
amino acids in 
urine 
30 min 
Ion Pair UHPLC 
Ionpair reagents: 
Tridecafluoroheptanoic 
acid 
Ion pair chromatography (Waterval, 
Scheijen, 
Ortmans-
Ploemen, Habets-
van der Poel, & 
Bierau, 2009) 
 
16 amino acids 60 min HILIC LC/MS/MS 
Allows for separation of isomers 
but long analysis time 
(Langrock, Czihal, 
& Hoffmann, 
2006) 
 
21 amino acids 10 min 
Monolithic Silica –FLD 
Derivatization with with 
4-fluoro-7-nitro-2,1,3-
benzoxadiazole (NBD-F) 
Fast method monolithic column 
but requires derivatization 
 
 
 
 
(Song, Funatsu, & 
Tsunoda, 2012) 
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Compound 
Class Analytes 
Analysis 
 time Instrumentation Comments Reference 
Amino Acids 32 amino acids 25 min CE-MS 
No derivatization required but 
long analysis time 
(Soga, Kakazu, 
Robert, Tomita, & 
Nishioka, 2004) 
 20 amino acids 5.5 min 
UHPLC-UV&CD 
Derivatization with 4-
fluoro-7-nitro-2,1,3-
benzoxadiazole 
(NBD-F) 
Fast analysis but not validated 
for biological samples 
(food samples)  
(Eto, Yamaguchi, 
Bounoshita, 
Mizukoshi, & 
Miyano, 2011) 
 
30 amino acids 30 min 
GC/MS 
Derivatization with 
propyl chloroformate 
Requires alternative 
instrumentation and 
derivatization 
(Kaspar, Dettmer, 
Gronwald, & 
Oefner, 2008) 
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1.2.2  Implementation of a high resolution chromatographic separation   
There is a growing need to incorporate chromatographic separation into the current 
newborn screening method for metabolism disorders (Bennett, 2009).  The current newborn 
screening method is acceptable for fast identification of certain metabolism disorders; however 
there is not sufficient selectivity to accurately identify many of these disorders. Also, some of 
the critical diagnostic markers are isobars which are not separated by flow injection analysis.  In 
addition, more specific markers are known for some of these metabolism disorders and have 
been implemented in second-tier tests, but are not included in the newborn screening.  By 
adding a chromatographic separation to the current newborn screening method, separation of 
isomers could be achieved and additional analytes could be added to the method.  A 
chromatographic separation would allow for differential diagnosis of several key metabolism 
disorders. Butryrlcarnitine (C4) and isobutryrlcarnitine (ISO C4) are examples of unresolved 
isomers which are diagnostic for separate disorders and can only be differentiated 
chromatographically.  Also not previously evaluated in newborn screening is the possibility that 
the matrix suppresses the ionization of analytes, potentially affecting the quantification.  In 
flow injection analysis the analytes are eluted as a plug, such that there is no separation of 
matrix components from the analytes.  Since there is no separation, there is the potential for 
analytes at higher concentrations to reduce the ionization of analytes at lower concentrations.  
This competing ionization can result in poor sensitivity and could potential increase errors in 
identification of a disorder. Employing a chromatographic separation could resolve matrix 
components from the analytes, improving the sensitivity and improving the quantification of 
the analytes.    
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1.2.3  Theory and approach for chromatographic separation   
Conventional high performance liquid chromatography has been unacceptable for 
newborn screening due to long analysis times and the inability to separate all of these 
compounds in a single analysis.  Innovations in ultra-high pressure liquid chromatography 
utilizing smaller particles and higher linear velocities, as shown by MacNair, Jorgenson and 
coworkers has been able to obtain high efficiency separations in short analysis times (MacNair, 
Lewis, & Jorgenson, 1997).  The theoretical plate height, which is a measure of a column’s 
efficiency, can be defined by the van Deemter Equation (Equation 1.3) (Miller, 2005).  
Minimizing the theoretical plate height (H) ultimately improves the columns efficiency.  Three 
kinetic interactions play a role in the column efficiency; eddy diffusion (A), molecular diffusion 
(B) and mass transfer (C).  The B and C terms are both influenced by the linear velocity (u) of 
the mobile phase. The optimal linear velocity (uopt) is dependent on particle size and diffusion 
of the anaylte in the mobile phase (Dm) (Equation 1.4) (MacNair et al., 1997).  Eddy diffusion (A) 
is directly related to the particle size (dp) and packing efficiency (λ) of the column (Equation 1.5) 
(Miller, 2005).  Therefore, smaller particles reduce eddy diffusion and improve column 
efficiency.     
  (Equation 1.3) 
(Equation 1.4) 
(Equation 1.5) 
Using smaller particles at optimal conditions reduces the theoretical plate height, which 
results in an increase the number of theoretical plates obtained per unit length of column. This 
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allows shorter columns packed with smaller particles to achieve similar performance as longer 
columns packed with larger particles.  Ultimately this reduces analysis times without sacrificing 
column efficiency.   
   Another critical aspect to our chromatographic separation is the stationary phase that 
was selected.  The stationary phase is critical to providing good chromatographic peak shape 
and acceptable retention.  There are several choices for stationary phases in liquid 
chromatography from very polar silica (Si-OH) phases to very non-polar C18 bonded stationary 
phases.  Conventional reverse phase columns, such as C18 stationary phases, retain hydrophobic 
analytes more than hydrophilic analytes.  However, several of the amino acids and 
acylcarnitines are extremely hydrophilic and they would not be well retained on a conventional 
C18 column unless they were derivatized first. An alternative stationary phase, called 
hydrophobic interaction chromatography or HILIC, employs a polar stationary phase and has 
been used to separate compounds with diverse polarity (Hemström & Irgum, 2006).   In 
addition, the elution order is reversed when compared to separations on a C18 column, 
hydrophilic solutes are more retained than hydrophobic.   
The basic HILIC stationary phase consists of an unmodified silica particle with Si-OH as 
the functional group, however there are also several bonded phases available (Hemström & 
Irgum, 2006).  The exact mechanism for retention of polar analytes is debated, although it is 
thought that multiple types of interactions can occur including; adsorption, electrostatic and 
dipole-dipole (Hemström & Irgum, 2006).   Adsorption of analytes into and out of a water 
solvated layer surrounding stationary phase particles appears to be a driving force for retention 
(Hemström & Irgum, 2006).  Therefore, hydrophilic analytes have a higher affinity for the water 
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and will partition into this layer more readily, increasing their retention.  Conversely, 
hydrophobic analytes will have a higher affinity for the mobile phase and are less retained. The 
overall result of this separation mechanism is longer retention for hydrophilic solutes than for 
hydrophobic solutes.  Modified silica bonded stationary phases provide alternative selectivity 
for HILIC retention, include; diol, cyanopropyl, amide, anion exchange, cation exchange and β-
cyclodextrin (Hemström & Irgum, 2006).  Hemström and Irgum have published a 
comprehensive review of all the different HILIC bonded phases that are commercially available 
(Hemström & Irgum, 2006).   Several of these stationary phases provide unique selectivity for 
acidic and basic compounds and while others are good for the separation of isomers.  Although, 
underivatized silica provides acceptable retention for polar solutes the amide bonded phase 
shows improve peak shape for basic compounds and requires less time for re-equilibration 
after gradient separation using buffers (Hemström & Irgum, 2006).  A major advantage to HILIC 
chromatography is the mobile phase is rich in organic solvent, which provides better 
desolvation, ultimately improving sensitivity for electrospray ionization (ESI).  Overall, HILIC 
chromatography provides a unique selectivity that is ideal for separation of for both 
acylcarnitines and amino acids.    
 The use of silica-bonded cyclodextrin as a secondary separation mechanism further 
enhances the selectivity of this chromatographic system allowing for the separation of critical 
isobars.  Cyclodextrins have been used to separate enantiomers, diasteriomers and structural 
isomers in multiple applications including CE, GC and HPLC (Ward & Baker, 2008).  The 
cyclodextrin ring is made up of multiple glucopyranosides attached together forming different 
size rings; α (alpha) - six member ring, β (beta) – seven member ring and γ (gamma) an eight 
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member ring (Tang & Ng, 2008).  The size of the ring is important to the enhancing the 
selectivity of this separation.  If compounds are too big to fit inside the cyclodextrin ring then 
there will not be any differences in retention of two isobars.  Also if both of the molecules easily 
fit into the cyclodextrin then the cyclodextrin will not provide added selectivity either.  The 
ideal case is when one of the two isomers will fit into the cyclodextrin and the other does not fit 
as well, due to steric hindrance or repulsive interactions with the surface of the cyclodextrin. 
There are various types of interactions that can occur between the cyclodextrin and the analyte 
molecule, including van der Waals, hydrophobic, electro static and hydrogen bonding (Li & 
McGuffin, 2007).  The interior of the cyclodextrin ring is hydrophobic, allowing for better 
retention of non-polar compounds; however the top of the cyclodextrin ring is more hydrophilic 
due to hydroxyl groups, allowing for better retention of compounds that can hydrogen bond 
with these hydroxyl groups.  Therefore the retention is related to its size and structure of the 
molecule, and is affected by its orientation and interaction with the cyclodextrin (Singh, Bharti, 
Madan, & Hiremath, 2010; Li & McGuffin, 2007).  This makes cyclodextrin an ideal phase for 
separating structural isomers, since one isomer will be generally more retained than the other. 
We combined both of these separation mechanisms to develop a rapid high resolution 
chromatographic separation for the analysis of acylcarnitines and amino acids.  The 
chromatographic separation can be conducted in approximately the same time as the current 
flow injection analysis.  In addition, we were able to chromatographically separate key isobars 
that are diagnostic markers for different metabolism disorders, improving the selectivity of the 
analysis.    
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1.3  Automated dried blood spot analysis 
1.3.1  Recent advancements in automation for dried blood spot analysis. 
Dried blood spot analysis has been extremely advantageous to newborn screening 
allowing for samples to be easily collected, shipped and stored.  However, the analysis of dried 
blood spots involves more complexities due to multiple processing steps that are typically done 
manually or with limited automation.  This slows down sample processing and adds to the 
workload of newborn screening laboratories.  Another disadvantage of dried blood spot 
analysis is a 3 mm punch has to be removed from the card for the analysis.  Once this spot is 
removed there is no way to directly track the sample back to the original card from which it was 
taken.  This lack of connection makes it difficult to ensure there are no samples that are mixed 
up due to processing errors.  Therefore, in order to improve the efficiency of dried blood spot 
analysis and to minimize the potential for processing errors, we investigated the ability to 
directly analyze newborn screening cards without the need to punch disks from the card.    
Others have also investigated the direct analysis of dried blood spots using similar 
approaches, however their research has been aimed at improving the efficiencies of dried 
blood spot analysis for use in clinical trials in pharmacokinetic studies to support new drug 
development (Barfield, Spooner, Lad, Parry, & Fowles, 2008; Beaudette & Bateman, 2004; Li & 
Tse, 2010; Spooner, Lad, & Barfield, 2009; Uyeda et al., 2011; Youhnovski et al., 2010) and for 
therapeutic drug monitoring (Edelbroek, Heijden, & Stolk, 2009).  This work has been a driving 
force in developing automated techniques so that hundreds of samples can be analyzed rapidly 
with little to no operator intervention.   Table 1.2 is a comprehensive list of articles published 
for the direct analysis of dried blood spots.  There are two primary designs that have been used 
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for direct analysis of dried blood spots; flow through and direct surface sampling.  The first 
device developed in 2009 required a disk to be punched from the dried blood spot and placed 
in a cartridge (Déglon, Thomas, Cataldo, Mangin, & Staub, 2009).  The cartridge was inserted in-
line with the mobile phase and the analytes were eluted off the DBS.   Although this approach 
was successful it was extremely labor intensive and time consuming, since every sample had to 
be individually processed.  This design was later automated in 2011 using multiple clamping 
devices to hold dried blood spots so that many samples could be analyzed, greatly improving 
the efficiency (Déglon et al., 2011).  An alternative approach was developed which involved 
direct sampling of the surface of the dried blood spot using a device similar to a TLC plate 
analyzer (Van Berkel & Kertesz, 2009).  There are several advantages to this device; samples can 
be processed without removing a punch, variable sample size can be analyzed and it could be 
incorporated with in-line sample clean-up prior to analysis. The TLC sampling device was 
pressed on the top of a dried blood spot and the mobile phase was used to elute the analytes. 
This device has been recently automated with robotic instrumentation improving sample 
through-put efficiency.     
Other techniques that have been published for the direct analysis of dried blood spots 
but they are not fully quantitative.  The first technique involves analysis using ionization by 
paper spray.  A small triangle of paper is placed in a clamp inside the ion source of the mass 
spectrometer.  Mobile phase is pumped to the paper and a voltage is applied to the clamp 
allowing for ionization of the analytes.  The analytes are eluted off the paper and are ionized 
and analyzed by mass spectrometry.   The second technique involves the use of direct electro 
spray ionization (DESI).  DESI employs an electrospray source that is directed at the sample’s 
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surface.  A solvent is pumped through the source which is ionized.  The charge from the solvent 
is transferred to the surface and analytes are ionized and pulled into the mass spectrometer.  
Both of these methods are direct ionization techniques in which the sample is directly analyzed 
just prior to the mass spectrometer.  Paper spray does allow for some  separation depending on 
the properties of the paper used, however DESI is a direct analysis without any 
chromatographic separation.  Although both of these techniques do allow for direct sampling of 
dried blood spots, neither of these techniques would be a dramatic improvement over the 
newborn screening method since they are only semi-quantitative techniques.  
Both the TLC interface and flow through device have been employed for the 
quantitative analysis of pharmaceutical compounds to support clinical pharmacokinetic studies 
(Déglon et al., 2011; Heinig et al., 2011).  These devices allow for quick analysis of DBS, and 
have been fully automated to reduce sample handling requirements, improving sample tracking 
with minimum off-line sample preparation.  However, there are still some concerns with direct 
analysis of dried blood spots including incorporation of an internal standard, dilution of out of 
range samples and correction for hematocrit-induced variations in sample volume. 
There have been multiple techniques used to add internal standard for on-line dried 
blood spot analysis.  The internal standard can be added to the sample prior to analysis either 
into the blood prior to spotting it on filter paper (Abu-Rabie & Spooner, 2009) or after the blood  
has dried (Déglon et al., 2009; Déglon et al., 2011).  Although both of these techniques appear 
to be acceptable they require additional sample handling that has to be done at the time of 
sample collection or sufficiently before sample analysis. Adding internal standard to the blood 
prior to spotting requires a larger volume of sample to be drawn, measured accurately before 
 28 
adding the internal standard.  This approach is not practical for newborn screening which is 
very simplistic and would add more complexity to the sample collection.  A recent technique 
was developed by Abu-Rabie et. al. uses a piezo electric spray device to add internal standard 
to the dried blood spot prior to analysis and allowing it to dry (Abu-Rabie et al., 2011).  An even 
coating of internal standard is sprayed across the surface of the dried blood spot and allows for 
the internal standard to bind to the matrix and paper components similarly to the analyte.  
Once the samples are dried the DBS is analyzed by a flow injection technique so that the 
internal standard elutes with the analytes.  This approach was acceptable for the analysis of 
acetominophen and sitamaquine using direct analysis with the TLC interface. Although adding 
the internal standard to the DBS prior to analysis appears to an acceptable technique, it adds 
additional sample handling requirements and delays time to analysis. An alternative approach 
would be to load a plug of internal standard into a loop and inject it through the DBS as the 
analytes are eluted (Heinig, Wirz, Bucheli, & Gajate-Perez, 2011).  This technique appears to be 
the best solution since it minimizes sample processing steps and can be easily integrated into 
most analytical systems.  
  
  
Table 1.2: Current approaches used for direct analysis of dried blood spots 
Technique Internal Standard 
Approach 
Analysis Comments Reference 
Flow through Added to DBS 
prior to analysis 
Saquinavir, Imipramine, Verapamil First Publication of on-line 
desorption of dried blood 
spots 
(Déglon et al., 2009) 
 Added to DBS 
prior to analysis 
Flurbiprofen and its metabolite 4-
hydroxyflurbiprofen 
Method was fully 
validated and used for the 
evaluation of a 
pharmacokinetic study 
(Déglon et al., 2011) 
TLC Internal Standard 
added to blood 
before spotting 
Acetaminophen, Sitamaquine, 
Propranolol  
First publication of TLC 
interface for dried blood 
spot analysis.  No 
chromatographic 
separation 
(Van Berkel & Kertesz, 
2009) 
 Internal Standard 
added to blood 
before spotting 
Acetaminophen, SB243213, 
Sitamaquine, Ibuprofen, 4-
Nitrophthalic acid Proguanil, 
Simvastatin, Benzethonium chloride  
Optimization of elution 
conditions  
(Abu-Rabie & Spooner, 
2009) 
 
 Evaluated internal 
standard addition 
to paper before 
and after spotting 
blood and on-line 
using loop 
injection  
Not given, pharmaceutical compound Incorporated column 
switching and on-line SPE 
cleanup 
(Heinig, Wirz, & Gajate-
Perez, 2010) 
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Technique Internal Standard 
Approach 
Analysis Comments Reference 
TLC Internal Standard 
added to blood 
before spotting 
Acetominophen and Sitamaquine Evaluated the robustness 
for direct analysis of DBS 
and dried plasma samples 
(DPS)  
(Abu-Rabie & Spooner, 
2011) 
 IS sprayed onto 
dried blood spot 
prior to analysis 
Acetominophen and Sitamaquine Evaluated the use of 
spraying IS onto DBS prior 
to analysis.  Samples were 
processed manually and 
with TLC interface   
(Abu-Rabie et al., 2011) 
 Internal standard 
added by loop 
injection on-line 
Oseltamivir (Tamiflu®) and  
Oseltamivir carboxylate 
Evaluated a new device 
that directly desorbs 
sample on-line with 
chromatographic 
separation  
(Heinig et al., 2011) 
Paper Spray Internal Standard 
added to blood 
before spotting 
Amitriptyline and Sitamaquine  Analysis of therapeutic 
Drugs in DBS  
(Manicke, Abu-Rabie, 
Spooner, Ouyang, & 
Cooks, 2011) 
 
 
 Added to DBS just 
prior to analysis 
Propranolol and Atenolol Evaluated the potential to 
analyze drugs in DBS 
using paper spray 
( Manicke et al., 2011) 
Paper Spray No Internal 
Standard 
Lidocaine, Amitriptyline,  
Sunitinib, Verapamil,  
Citalopram 
Analysis of therapeutic 
drugs in DBS using silica 
coated paper substrate 
(Zhang, Xu, Manicke, 
Cooks, & Ouyang, 
2012) 
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Technique Internal Standard 
Approach 
Analysis Comments Reference 
 Internal Standard 
added to blood 
before spotting 
Analysis of Acylcarnitines Similar to flow injection 
analysis, no 
chromatography shown 
(Yang et al., 2012) 
DESI Internal Standard 
was added to the 
blood prior to 
spotting 
 
Prazosin, Sitamaquine, Terfenadine 
and Verapamil 
DBS were directly 
analyzed using desorption 
electrospray ionization 
No Chromatographic 
separation, analysis is 
only semi quantitative   
(Wiseman, Evans, 
Bowen, & Kennedy, 
2010) 
Micro 
Extraction 
Internal Standard 
added to blood 
before spotting 
Verapamil, Sitamaquine, propranolol 
sulforaphane, sulforaphane N-acetyl 
cysteine (NAC) conjugate, 
sulforaphane glutathione (G) 
conjugate 
Liquid micro extraction of 
DBS using Advion 
NanoMate chip-based 
infusion 
Directly extracts analytes 
off the surface of the 
sample and infuses them 
into the mass 
spectrometer 
(Kertesz & Van Berkel, 
2010) 
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1.3.2  Advantages of direct DBS analysis for newborn screening 
Newborn screening is a labor intensive process requiring samples to be processed by 
multiple methods.  In addition, the typical work load for a newborn screening laboratory ranges 
from 350 to 1500 samples per day (Chace, 2009).  Multiple technicians and experienced 
chemists are required to process and analyze all these samples and results need to be reported 
as soon as possible so that treatment can be started for affected children.  Overall, this is an 
ideal environment to employ automated techniques, to improve laboratory efficiency and 
reduce operating costs (Hamilton, 2007).  Implementation of direct analysis of dried blood 
spots could provide a dramatic benefit to newborn screening.  Also sample tracking and data 
analysis could be directly linked using automation devices such as bar code readers, reducing 
sample processing errors.  
1.3.3  Development of an in-line desorption device for dried blood spot analysis 
In order to address the needs of newborn screening, we have developed an in-line 
desorption device for direct measurement of the dried blood spot without the need punching 
disks from the filter paper cards eliminating off-line sample processing.  This device will 
minimize human intervention and reduce misidentification of samples due to processing errors. 
Our approach involves clamping a dried blood spot between two in-line filters which provides a 
leak free seal.  We tested the sealing properties for our device under various conditions to 
ensure the integrity of the sample was not compromised.  The elution parameters were 
optimized to determine the most effective solvent composition and flow rate to quickly and 
efficiently elute the analytes.  Finally the device was incorporated with chromatographic 
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separation using an Acquity UPLC HILIC Amide column to separate leucine, isoleucine and 
hydroxyproline, which are commonly analyzed in second-tier testing for MSUD.       
1.4  Factors affecting sample volume in dried blood spot analysis 
1.4.1  Evaluation of hematocrit in dried blood spots 
Another critical issue in dried blood spot analysis is defining the sample volume from an 
excised spot.  It is well known that sample volume for dried blood spots is dependent on the 
patient’s hematocrit (Mei, Alexander, Adam, & Hannon, 2001).  Hematocrit is defined as the 
density of red blood cell per unit volume of blood.  Samples with a high hematocrit will have 
more red blood cells than samples with a low hematocrit.  This is important because the 
hematocrit affects the viscosity of the blood which in turn will affect the diffusion properties of 
blood on the filter paper. Newborn screening cards are tested to ensure that blood with a 
specified hematocrit will diffuse consistently to reduce lot to lot variability (Mei et al., 2001).  
However, samples with a high hematocrit do not diffuse as far as samples with a low 
hematocrit.  It has been shown that the plasma volume can vary by as much as 47% from a 
sample with low hematocrit to a sample with high hematocrit (Mei et al., 2001). Table 1.3 is a 
comprehensive list of publications related to the effect of hematocrit on dried blood spot 
analysis.  
In order to correct for differences in hematocrit Li et. al. have suggested spotting a 
known volume of blood on perforated filter paper and analyzing the entire spot (Li, Zulkoski, 
Fast, & Michael, 2011).  Although this has been shown to work for analysis of pharmaceutical 
compounds in blood for pharmacokinetic studies this technique is not ideal for newborn 
screening.  Newborn screening relies on a simplistic sample collection approach where the 
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newborns heal is pricked with a lance and the blood is spotted on the filter paper by dabbing 
the paper on the newborn’s heal.  Spotting an exact amount of blood would require health care 
providers to draw blood from the child, collect the sample in a tube and then pipet a specified 
volume on the card.  Although this would alleviate the concern related to sample volume it 
would introduce additional complexities to the current sample collection procedure and could 
cause errors related to inaccuracies in pipetting.  
If the hematocrit of the blood could be determined at the time of sample collection then 
it could be used to estimate sample volume at the time of analysis.  Although this could be 
done by the health care providers at the time of sample collection it would increase the work 
load and requires additional instrumentation for the analysis.    An alternative approach would 
be to determine the hematocrit of the dried blood spot at the time of sample analysis.  This has 
been previously attempted using the newborn screening test for hemoglobinopathies (Orsini, 
Yeman, Bodamer, Mühl, & Caggana, 2010).  This test is a semi-qualitative method for the 
analysis of hemoglobinvariants F, A, S, D, C, and E.  Samples are analyzed by HPLC UV at 415nm 
and the peak areas of the different hemoglobin forms are summed together to get total 
hemoglobin.  The data was then used to relate hemoglobin content to hematocrit (Orsini et al., 
2010).  Although there was a good correlation between hemoglobin and hematocrit the 
acceptability of the method was questionable.  They reported an overall percent accuracy of 
108% with a range of 73.5–142%.  Although there does appear to be some issues with the 
accuracy, this method shows feasibility to determine hematocrit in dried blood spot samples. 
Once the hematocrit level is determined it can be used to estimate sample volume from a 
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predetermined punch size, eliminating the need to pipette specified volumes on the filter 
paper.   
  
Table 1.3: Reported issues related to hematocrit effect on sample volume in dried blood spot analysis 
Analytes Investigation Comments Reference 
Acetaminophen and 
sitamaquine  
Evaluate the effect of 
hematocrit on assay bias when 
using DBS samples for the 
quantitative bioanalysis of 
drugs 
 
Showed little bias in sample 
volume within normal range, 
however only 15 µL of blood was 
spotted on cards.  Only two 
analytes investigated 
(Denniff & Spooner, 
2010) 
 125I-L-Thyroxine Evaluated the influence of 
hematocrit and sample volume 
added to filter paper 
 
Showed that analyte 
concentrations were significantly 
different between 75 µL and 100 
µL blood was spotted on cards 
(O'Broin, 1993) 
 125I-L-Thyroxine Evaluated hematocrit effects 
on sample volume and 
potential chromatographic 
effects. 
 
Approximately a 50% difference 
in sample volume between 30% 
and 70% hematocrit.  Only a 13% 
difference in sample volume was 
observed for peripheral punch 
and center punch  
(Mei et al., 2001) 
Phenylalanine Evaluated the combined 
effects of hematocrit, loading 
blood volume and filter paper 
source. 
 
Combined effect of 
approximately 30% was observed 
for phenylalanine concentrations  
   
(Adam et al., 2000) 
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Analytes Investigation Comments Reference 
Amino acids and acylcarnitines  Evaluate the effect of 
hematocrit and  punch location 
for DBS analysis  
 
Dramatic differences in analyte 
concentrations were observed 
for low and high hematocrit 
samples.  Some analyte 
concentrations in peripheral 
punches were significantly 
different than for center punches   
(Holub et al., 2006) 
 Cyclosporin A Evaluated hematocrit effects in 
DBS samples 
 
No significant differences from 
30% to 56% hematocrit were 
observed for a 50 µL spot and a  
8 mm punch 
(Wilhelm, den Burger, 
Vos, Chahbouni, & 
Sinjewel, 2009) 
Compounds with diverse 
lipidpholicity 
Evaluated the effects of 
hematocrit and punch location 
on assay bias with a variety of 
filter papers. 
 
Significant differences were 
observed for different hematocrit 
levels and for center versus 
peripheral punch locations 
(O'Mara, Hudson-
Curtis, 
Olson,Yueh,Dunn,Spoo
ner, 2011) 
Unknown compound Evaluated the effect of sample 
volume on blood spot 
diameter on DMPK-B and 
DMPK-C filter paper cards.  
The diffusion properties of the 
two papers were dramatically 
different. The DMPK-C paper 
diffused much more evenly.  
Analyte concentration increased 
up to about 50 µL of blood then 
leveled off. 
(Fan et al., 2011) 
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1.4.2  Background and theory of diffuse reflectance 
There are several published papers that have been reported using reflectance as a tool 
to analyze properties of blood and blood components in vitro and in vivo for decades (Johns, 
Giller, & Liu, 2001; Meinke, Gersonde, Friebel, Helfmann, & Müller, 2005; Schmitt, Meindl, & 
Mihm, 1986; Serebrennikova, Smith, Huffman, Leparc, & García-Rubio, 2008; Steinke & 
Shepherd, 1986; Steinke & Shepherd, 1988; Steinke & Shepherd, 1988; S. Zhang, Soller, Kaur, 
Perras, & Salm, 2000; Zijlstra, Buursma, & Meeuwsen-van der Roest, 1991; Zonios & Dimou, 
2006).  The main advantage to reflectance is that it is a non-destructive technique and can be 
used to directly analyze samples without the need for any preprocessing.  Although there have 
been several reported papers that evaluate hematocrit in vivo and in vitro using reflectance 
these methods are only applicable to red blood cells in solution.   An alternative approach 
would be required to determine the hematocrit in dried blood spot analysis.  Dried blood spot 
analysis is more closely related to the analysis of surfaces which are commonly analyzed using 
diffuse reflectance techniques. 
Diffuse reflectance has been used to analyze solid samples including; paint, soil, paper, 
coal food and biological samples (Subhash et al., 2006; Ulery, Drees, & Soil Science Society of 
America, 2008; Wesley & Wendlandt, 1966; Yu et al., 2008).  The principle of diffuse reflectance 
is used to explain multiple interactions that reflected light has with a mat or rough surface 
(Ulery et al., 2008; Wesley & Wendlandt, 1966).  When light is directed at a rough surface the 
light is variously reflected, scattered, refracted and absorbed.   In order to better understand 
diffuse reflectance one must first understand the basics of specular reflectance. In the most 
simplistic case, when light is reflected from a smooth surface it can be defined by the Fresnel 
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equation, Equation 1.6, where the reflected light (R) is dependent on the incident radiant 
energy (Io) and the intensity of the light reflected (I). 
 
The radiant energy of the incident light and reflected light is dependent on the refractive index 
(n) of the medium and the absorption index (k) (Wesley & Wendlandt, 1966). The angle (θ1) of 
the incident light from a normal perpendicular to the surface will be the same as the reflected 
angle (θ2) (Figure 1.5).  The intensity of the light reflected from the surface will be dependent 
on the amount of light absorbed by the sample (k) and the amount of light that penetrates the 
sample (n2). Reflectance of smooth surfaces such as these are commonly performed to 
determine the absorption properties or refractive index of a material.  However, the surface 
must be smooth and the crystalline structure of the material must not diffuse light.      
 
 
 
 
Figure 1.4: Diagram to show the difference between how light is reflected by specular 
reflectance and diffuse reflectance 
 
(Equation 1.6)  
Diffuse Reflectance Specular Reflectance 
θ1 θ2 
n1 
n2 
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Diffuse reflectance is more complex then spectral reflectance and no theories are 
completely valid for all cases (Wesley & Wendlandt, 1966).  In diffuse reflectance light is 
scattered in multiple directions depending on the crystal structure of the material and/or the 
roughness of the surface (Figure 1.4).  For a non-absorbing surface where the radiation is 
scattered homogeneously in all directions, the Lambert Cosine Law can be used, Equation 1.7 
(Wesley & Wendlandt, 1966), 
Lambert Cosine Law:               (Equation 1.7) 
where B is the intensity of the radiant light, α is the angle of the incident light and θ is the angle 
of the reflected light.  The Lambert Cosine Law was shown to be valid for non-absorbing 
powders at certain angles, however at some angles the results were unacceptable (Wesley & 
Wendlandt, 1966).  Absorbing materials add additional complexity to developing theoretical 
models, since some of the light is absorbed by the sample or penetrates into the sample 
altering the properties of the reflected light.    
Reflectance properties of blood and tissue samples have been extensively investigated.  
One group investigated the reflectance properties of tissue samples indicated that the reflected 
light was dependent on the size and density of cellular components (Yu et al., 2008).  It has also 
been reported that the optical absorbance of the red blood cells in vitro solutions affect the 
intensity of light that is reflected and light scattering properties were related to hematocrit 
(Lovell, Hebden, Goldstone, & Cope, 1999).  Although these measurements were made in 
different media from a dried blood spot, it does show the potential to measure the intrinsic 
properties of blood using reflectance. Our approach is based on the phenomena that as the 
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hematocrit increases the red blood cell density increases across the surface of the dried blood 
spot and the surface will scatter and absorb light depending on the concentration of the cellular 
components.      
1.4.3  Diffuse reflectance of dried blood spots 
 In order to correct sample volume for differences in hematocrit on dried blood spots, 
we have investigated the use of UV/NIR reflectance to relate hematocrit.  By relating 
hematocrit to a UV/NIR measurement we can then estimate sample volume from a predefined 
punch size.  We will test our approach with donor samples prepared at various hematocrit 
levels and fortified at known concentrations with acylcarnitines C0, C2, C3, C4, C5, C6, C8, C10, 
C12, C14, C16 and C18.  Correcting for sample volume should improve the accuracy of newborn 
screening potentially improving the positive predictive value and will reducing errors associated 
with not correcting sample volume for high and low hematocrit levels.  
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CHAPTER 2 
 
A QUANTITATIVE METHOD FOR ACYLCARNITINES AND AMINO ACIDS 
USING HIGH RESOLUTION CHROMATOGRAPHY AND TANDEM MASS 
SPECTROMETRY  IN NEWBORN SCREENING DRIED BLOOD SPOT 
ANALYSIS 
 
Drawn from manuscript published in Journal of Chromatography B, 903(2012) 142-149.  
 
2.1.  Introduction 
Newborn screening is claimed to be “one of the most successful public health programs” 
(Sahai & Marsden,2009) ever initiated and originated with Robert Guthrie screening for 
phenylketonuria (PKU) (Guthrie & Susi, 1963).  Since its inception, additional markers have been 
identified for different disorders and added to the panel of screening tests.  However, most of 
these methods required a separate analysis for each disorder.  It wasn’t until a method was 
developed by researchers at Duke University that multiple heritable metabolic disorders could 
be identified in a single test (Millington et al., 1990).   This approach relied on a technique 
called flow injection in which samples were directly injected onto the mass spectrometer 
without chromatographic separation.  Mass spectra were extracted from the data allowing for 
identification of metabolic disorders based on elevated levels of specific acylcarnitines.   Over 
the years additional analytes were added to this screening method allowing for early detection 
of more than 20 different metabolism disorders in a single analysis (Chace et al., 2003; 
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Sweetman, 2001).  Although this approach has proven to be successful and provides a rapid 
screening test for many disorders, the analysis is not fully quantitative (Sahai & Marsden, 2009), 
and screen positive results often need to be confirmed by a second-tier test (Lehotay et al., 
2011).   
One major disadvantage with this flow injection approach is its inability to differentiate 
isobaric species associated with different metabolic disorders resulting in additional testing to 
identify the specific disorder (Bennett, 2009; Matern et al., 2007; Sahai & Marsden, 2009; 
Sweetman, 2001). Chromatographic separation is required to separate these isobars, however 
current approaches involve lengthy analysis times (Maeda et al., 2007), use ion pair reagents 
(Piraud et al., 2005) or require additional instrumentation such as capillary electrophoresis 
(Chalcraft & Britz-McKibbin, 2009).  Another potential problem for a flow injection approach is 
quantification using a single point response factor with stable isotope labeled internal 
standards.  Assuming that the responses of the isotopically labeled internal standards are 
equivalent to their corresponding analyte can lead to inaccuracies in quantification and 
fluctuations in quantification limits.  It has been reported, that the response factors of the 
analytes and internal standards must be evaluated to accurately quantify analytes (De Jesús, 
Chace, Lim, Mei, & Hannon, 2010). Chace and coworkers have reported the quantification of 
leucine can be impacted by unresolved isobaric species that have different response factors 
(Chace et al., 1995). Although this research allowed for the identification of MSUD, it also 
shows that response factors can be affected by unresolved isobars. Not previously discussed 
regarding newborn screening, is the potential for response factors to be affected by matrix 
effects.  Although, stable isotope labeled internal standards reduce errors associated with 
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matrix suppression there are reports that show analyte to internal standard response ratios can 
be affected (Jemal, Schuster, & Whigan, 2003; Lindegardh et al., 2008; Trufelli, Palma, Famiglini, 
& Cappiello, 2011).   In addition, since there is no chromatographic separation employed in the 
flow injection screening method, ionization can be reduced by the presence of matrix related 
components or by other analytes at higher concentrations (Trufelli et al., 2011).  This could 
result in the misidentification of samples close to the cut-off value, if the matrix suppression 
reduces or enhances the ionization of an analyte differently than its corresponding internal 
standard.   
The original and still widely used approach for flow injection analysis involves 
derivatization of acylcarnitines and amino acids with n-butanol and HCl to form butyl esters 
which enhances the sensitivity of certain analytes (Chace et al., 2003).  However, the caustic 
nature of this derivatization is a safety hazard to laboratory personnel and hydrochloric acid is 
corrosive to laboratory equipment.  More recently a method has been developed without 
derivatization, but this approach may result in lower intensity for specific dicarboxylic acid 
acylcarnitines (De Jesús et al., 2010).  Although both of these techniques have been shown to 
provide acceptable results for screening purposes there is still the potential for a high false 
positive rate for some disorders (Matern et al., 2007; Sahai & Marsden, 2009).  This has 
resulted in the need for implementation of second-tier tests to identify certain disorders 
(Matern et al., 2007; Sahai & Marsden, 2009).  The current approach to confirm specific 
disorders is one second-tier test for each disorder, resulting in multiple second-tier tests that 
have to be used by newborn screening laboratories and/or physicians.  To date there is not a 
comprehensive second-tier test able to quantify acylcarnitines and amino acids in a single 
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analysis.  Common practice for quantitative analysis of acylcarnitines and amino acids profiles 
requires a second blood sample to be drawn from the infant and sent to a clinical laboratory for 
analysis.  This can result in unnecessary parental anxiety for false positive cases and further 
delaying the time to diagnosis.  Therefore, there is a need for a rapid second-tier test that could 
be used to improve identification of the confounding disorders associated with results obtained 
by flow injection newborn screening methods.            
Typical methods employed by clinical laboratories for quantitative analysis of 
acylcarnitines and amino acids are not usually available within public health newborn screening 
laboratories.  In addition, these methods are not commonly performed together, so samples 
are analyzed by separate procedures using different instruments. The reported methods for 
acylcarnitines are not practical for second-tier testing due to long analysis times (Maeda et al., 
2007; Maeda et al., 2008; Zuniga & Li, 2011), poor chromatography (Ghoshal et al., 2005), or 
involve alternative instrumentation such as capillary electrophoresis (Chalcraft & Britz-
McKibbin, 2009).  There are many methods available for amino acid analysis; however, the 
majority involves derivatization of samples followed by HPLC-UV, FLD, LC/MS or GC/MS (Kaspar 
et al., 2009).  These methods typically have analysis times longer than ten minutes and require 
costly derivatization techniques to enhance sensitivity and retention.    One published method 
for the analysis of amino acids does not require derivatization; however the analysis time is 50 
minutes (Langrock, Czihal, & Hoffmann, 2006), which would be unacceptable as a rapid second-
tier test.  Our method is the first comprehensive method capable of chromatographically 
separating twelve acylcarnitines and seven amino acids in 2.2 minutes, with a total injection to 
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injection cycle time of 3.1 minutes, a dramatic improvement over all other previously reported 
techniques.   
The combination of high resolution chromatography and the unique selectivity of HILIC 
stationary phase are ideal for fast chromatographic separation of both amino acids and 
acylcarnitines without the need for derivatization or ion pair reagents.  It has been reported 
that ultra-high pressure liquid chromatography using smaller particles and higher linear 
velocities are able to achieve high efficiency separations in faster analysis times compared to 
conventional HPLC separations (MacNair et al., 1997).  In addition, polar stationary phases such 
as hydrophilic interaction liquid chromatography (HILIC) are better suited to retain diverse 
polarity analytes and offer improved sensitivity over reverse phase chromatography (Hemström 
& Irgum, 2006). The basic HILIC stationary phase consists of an unmodified silica particle with 
Si-OH as the functional group, however there are also several modified silica phases that are 
commercially available (Hemström & Irgum, 2006).  Although the unmodified phase has been 
widely used for HILIC chromatography the HILIC amide phase provides better peak shape for 
basic analytes and takes less time to re-equilibrate between injections (Hemström & Irgum, 
2006).  Using both UHPLC and HILIC allowed us to developed a complementary rapid method 
that could be used by newborn screening laboratories to identify fatty acid oxidation disorders, 
amino acid metabolism disorders and organic acid disorders.   In addition, the chromatographic 
separation resolves leucine, isoleucine and hydroxyproline allowing for confirmation of MSUD, 
which is not possible with the flow injection methods.   This analysis is performed with the 
same sample extract used in the non-derivatized screening method to rapidly confirm abnormal 
screening results.  In addition, quantification is based on a full calibration using reference 
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standards prepared in whole blood and dried on newborn screening cards.  Alternative 
conditions were used to resolve butyrylcarnitine (C4) from isobutyrylcarnitine(ISO C4) along 
with valerylcarnitne(C5) from isolvalerylcarninte (ISO C5) which would allow for differential 
diagnosis for short chain acyl-coenzyme A dehydrogenase deficiency(SCAD) and isobutyryl-CoA 
dehydrogenase deficiency(IBCD) or isovaleric academia (IVA).  This methodology provides 
newborn screening laboratories with a complementary rapid second-tier test which is able to 
confirm multiple metabolism disorders in a single analysis.    
 
2.2  Materials and methods 
2.2.1  Materials and reagents  
Acylcarnitine reference standards (purity > 95%) were purchased from VU Medical 
Center Metabolic Laboratory, (Amsterdam, The Netherlands) and amino acid reference 
standards (purity > 96%) were purchased from Sigma Aldrich (Milwaukee, WI, USA). Stable 
isotope labeled amino acids and acylcarnitines reference materials (purity > 98%) were 
obtained from Cambridge Isotopes (Andover, MA, USA). Hydroxyproline obtained from ARCOS 
Organics (Morris Plains, NJ, USA) was used as a system check to confirm the retention time.  
HPLC grade acetonitrile, formic acid and ammonium formate were from Fisher Scientific 
(Pittsburgh, PA, USA). Control human sodium heparin whole blood was obtained from 
Biochemed (Winchester, VA, USA).  Newborn screening cards, 903 Protein Saver, were obtained 
from Whatman (Piscataway, NJ, USA).  A 22 Multiple Syringe Pump from Harvard Apparatus 
(Holliston, MA, USA) and a 250 µL Hamilton gas tight syringe from Fisher Scientific (Pittsburgh, 
PA, USA) was used for infusion tests.    
 48 
2.2.2  Chromatographic  instrumentation 
Chromatographic separations were conducted with a Waters Acquity HILIC Amide 
column, 2.1 x 50 mm, 1.7 µm; Waters Corp. (Milford, MA, USA). Separation of C4 and C5 
isomers was achieved by placing a Supelco Astec CYCLOBOND™ I 2000 Chiral HPLC guard 
column, 1.0 x 20 mm, 5 µm from Sigma Aldrich (Milwaukee WI, USA) prior to the HILIC Amide 
column.   A Waters Acquity UPLC pump and sample manager were used for analysis and 
gradient separation.  A Waters Premier triple quadrupole mass spectrometer (Milford, MA, 
USA) equipped with electrospray ionization (ESI) source in positive ion mode was used.  
Optimization of the instrument parameters including desolvation temperature, source 
temperature, desolvation gas flow, cone gas flow, capillary voltage, cone voltage and collision 
energy was performed by direct infusion of a solution containing acylcarnitines, amino acids 
and their labeled internal standards.  Optimal sensitivity was achieved using 3.8 kV for the 
capillary, 390 oC desolvation temperature with nitrogen as the desolvation gas at a flow of 800 
L/hr. Cone gas was nitrogen at a flow of 20 L/hr with a source temperature of 110 oC.  Argon 
was used for the collision gas at a flow of 0.4 L/hr. Multiple reaction monitoring (MRM) was 
used for all analytes and internal standards.  Specific transitions were used for each compound 
with optimized cone voltage and collision energy shown in Table 2.1.  In order to monitor for all 
these transitions, MRMs were scheduled based on the retention time of each analyte to 
achieve a minimum 0.4 minute window around each peak with a 0.02 second dwell time and a 
0.02 second inter-scan delay.       
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Table 2.1: Acylcarnitines and amino acids analyzed and the mass spectral settings for MRM 
mode 
Analyte ID CV  (V) 
CE  
(eV) 
MRM 
Transition I.S. 
I.S. MRM 
Transition 
Time segment 
(min) 
Carnitine C0 22 20 161.9→84.6 C0-D9 170.9→84.6 1.73 to 2.03 
Acetylcarnitine C2 22 20 203.9→84.6 C2-D3 206.9→84.6 1.57 to 1.87 
Propionylcarnitine C3 22 20 217.9→84.6 C3-D3 220.9→84.6 1.43 to 1.73 
Butyrylcarnitine C4 22 21 231.9→84.6 C4-D3 235.0→84.6 1.31 to 1.61 
Valerylcarnitine C5 22 23 246.0→84.6 C5-D9 255.1→84.6 1.21 to 1.51 
Hexanoylcarnitine C6 22 23 260.0→84.6 C8-D3 291.1→84.6 1.10 to 1.40 
Octanoylcarnitine C8 22 23 288.1→84.6 C8-D3 291.1→84.6 0.97 to 1.27 
Decanoylcarnitine C10 22 28 316.1→84.6 C8-D3 291.1→84.6 0.80 to 1.10 
Lauroylcarnitine C12 22 28 344.1→84.6 C14-D9 381.2→84.6 0.63 to 1.01 
Myristoylcarnitine C14 22 28 372.1→84.6 C14-D9 381.2→84.6 0.63 to 1.01 
Palmitoylcarnitine C16 22 28 400.2→84.6 C16-D3 403.2→84.6 0.00 to 0.95 
Stearoylcarnitine C18 22 28 428.2→84.6 C16-D3 403.2→84.6 0.00 to 0.95 
Phenylalanine Phe 20 15 165.8→119.7 Phe-D6 171.8→125.7 1.37 to 1.67 
Leucine/Isoleucine Leu/Ile 18 11 131.8→85.7 Leu-D3 134.85→88.7 1.41 to 2.03 
Methionine Met 14 11 149.8→103.6 Met-D3 152.85→106.6 1.50 to 1.80 
Tyrosine Tyr 15 14 181.8→135.8 Tyr-D6 187.8→141.8 1.54 to 1.84 
Valine Val 20 8 117.8→71.8 Val-D8 125.8→79.7 1.60 to 1.90 
Citrulline Cit 16 10 175.8→158.7 Cit-D2 177.8→160.7 1.88 to 2.18 
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2.2.3  Preparation of dried blood spots 
For the validation portion of this study, sodium heparinized human whole blood was 
fortified at 6 levels for a calibration curve and at 4 additional levels for quality control samples.  
Individually prepared reference standards containing acylcarnitines and amino acids were 
spiked into whole blood to fortify samples at the desired concentration to prepare the highest 
calibration standard and quality control sample.  These samples were then serially diluted to 
prepare the additional calibration levels and quality control samples.   Each dried blood spot 
was prepared by spotting 50 µL of sample onto a Whatman, 903 Protein Saver newborn 
screening card.  These samples were allowed to dry for at least 2 hours at room temperature 
and then stored at 0-5 oC until analyzed.  
2.3.  Results and discussion 
2.3.1  Response factor evaluation 
In newborn screening, response factors are used to quantify analytes and set cut-off 
values to help identify children at risk of having a metabolic disorder. The analyte concentration 
is determined based on Equation 2.1 where the response factor is often not calculated and 
assumed to be equal to one.  However, this assumption can lead to errors in calculated 
concentrations if the response factors deviate from one.  We evaluated the response factors for 
all analytes using both external solutions and extracted samples to determine if the sample 
matrix had a significant effect on the response factors.  The analyte response factors were 
initially determined for each analyte by flow injection analysis without derivatization using 
external standards containing both analytes and internal standards.  External standards were 
prepared such that the final concentrations of the analytes and internal standards were 
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equivalent.  Serial dilutions were made to achieve five-point response curves with 
concentrations above and below target concentration of internal standard in the final extract.   
For flow injection analysis, 3 replicate injections of an external standard containing analytes and 
internal standards were injected onto the LC/MS/MS system and the response from 50 scans 
were averaged, which is the maximum number of scans across the center of the elution plug.  
The responses of each analyte and their respective isotopically labeled internal standard were 
evaluated.  Data for carnitine and acetylcarnitine were plotted to show the relationship 
between response and concentration, Figures 2.1A and 2.1B respectively.  Equation 2.2 was 
used to calculate the response factors for each analyte and its isotopically labeled internal 
standard at various concentrations. The response factors for all the analytes were plotted 
versus concentration to evaluate if the response factors were consistent across the 
concentration range.  Example plots for response factors for carnitine and acetylcarnitine are 
shown in Figures 2.2A and 2.2B respectively.  The average response factors were calculated by 
averaging the response factor across all concentrations and results are reported in Table 2.2. 
 
Equation 2.1: Conventional calculation for concentration for analytes extracted from dried 
blood spots 
 
Equation 2.2: Response factor determined using the instrument response for an analyte and 
internal standard analyzed at identical concentrations 
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Equation 2.3: Calculation of accuracy for the response factor determined using internal 
calibration curve 
 
 
 
 
  
Legend: Carnitine (squares) and carnitine-D9 (diamonds) for external standards using flow 
injection analysis.  Each sample analyzed in triplicate, error bars represent 1 S.D.. 
 
Figure 2.1A: Plot of external standard response (n =3) versus concentrations for carnitine and 
carnitine-D9, samples analyzed by LC/MS flow injection analysis with precursor ion scan 
mode for the production of 85 m/z 
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Legend: Acetylcarnitine (squares) and acetylcarnitine-D3 (diamonds) for external samples using 
flow injection analysis.  Each sample analyzed in triplicate, error bars represent 1 S.D.. 
Figure 2.1B: Plot of external standard response (n=3) versus concentration for acetylcarnitine 
and acetylcarnitine-D3, samples analyzed by LC/MS flow injection analysis with precursor ion 
scan mode for the production of 85 m/z  
 
 
Legend: Each sample analyzed in triplicate, error bars represent 1 standard deviation 
Figure 2.2A: Plot of calculated response factors (n=3) for external standards containing 
carnitine and carnitine-D9, evaluated at five different concentrations, samples analyzed by 
LC/MS flow injection analysis with precursor ion scan mode for the production of 85 m/z   
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Legend: Each sample analyzed in triplicate, error bars represent 1 standard deviation 
Figure 2.2B: Plot of calculated response factors (n=3) for external standards containing  
acetylcarnitine and acetylcarnitine-D3, evaluated at five different concentrations, samples 
analyzed by LC/MS flow injection analysis with precursor ion scan mode for the production of 
85 m/z   
The response factors in extracted dried blood spot samples were evaluated using the 
flow injection analysis technique described above.  Internal standard stock solutions were 
prepared in the appropriate solvent identified by Cambridge Isotopes and diluted 200-fold in 
the extraction solvent to achieve the appropriate concentration used in the established 
newborn screening method.  A 3.0 mm sample was punched from a dried blood spot quality 
controls sample and placed in a 96-well plate.   Three replicates of each sample were extracted 
in 100 µL of methanol with 0.1% formic acid containing labeled internal standards.  Samples 
were vortexed for 30 minutes vigorously and then 70 µL was transferred to a clean 96-well 
plate for analysis. These samples were analyzed by flow injection analysis for acylcarnitines and 
amino acids.  The calculated concentration was determined using the response ratios with the 
appropriate labeled internal standard and then multiplying by the concentration of the internal 
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standard and the dilution factor as shown in Equation #2.1.  In addition, these samples were 
quantitated using an internal calibration curve and the back-calculated concentrations were 
used to determine the actual concentration of the analyte in the sample.  Using Equation #2.3, 
the accuracy of the response factor of 1 was determined for each analyte.  The accuracy value 
can be then be multiplied by 1 to obtain the actual response factor for the extracted samples 
which is reported in Table 2.2. 
Table 2.2: Evaluation of response factors for external standards and extracted samples 
Three replicates at 5 levels were analyzed (n=15) for externals. Three replicates at 4 levels were analyzed (n=12) 
for extracted samples.  *p-value was used to test if the mean is different than 1.0 using JMP 9.0.0 software. Bold  
p-values indicate significant differences 
 
From our results, it is apparent that the response factors determined for external 
standards are different than the response factors determined for extracted samples for all  
Analyte 
Response 
Factors for 
External 
Standards 
S.D. %RSD p-value* 
Response 
Factor for 
Extracted  
Samples 
S.D. %RSD p-value* 
C0 1.26 0.0238 1.89% < 0.05 1.09 0.0649 5.94% < 0.05 
C2 0.642 0.0151 2.35% < 0.05 1.53 0.137 8.95% < 0.05 
C3 0.792 0.0530 6.69% < 0.05 1.26 0.148 11.7% < 0.05 
C4 0.906 0.0268 2.96% < 0.05 1.31 0.0616 4.70% < 0.05 
C5 1.13 0.0344 3.05% < 0.05 1.27 0.0851 6.70% < 0.05 
C6 1.19 0.0361 3.02% < 0.05 1.13 0.0772 6.83% < 0.05 
C8 0.905 0.0267 2.95% < 0.05 0.931 0.120 12.9% 0.249 
C10 0.728 0.0283 3.89% < 0.05 0.713 0.119 16.7% < 0.05 
C12 0.963 0.0287 2.98% < 0.05 0.883 0.129 14.6% < 0.05 
C14 0.897 0.0251 2.80% < 0.05 0.829 0.117 14.1% < 0.05 
C16 1.01 0.0299 2.95% 0.0742 0.976 0.114 11.7% 0.315 
C18 1.10 0.0471 4.26% < 0.05 1.16 0.141 12.1% < 0.05 
Phe 0.931 0.00694 0.746% < 0.05 1.29 0.0841 6.50% < 0.05 
Leu/Ile 0.932 0.00461 0.495% < 0.05 1.22 0.105 8.62% < 0.05 
Tyr 1.16 0.0626 5.42% < 0.05 1.82 0.120 6.60% < 0.05 
Val 1.15 0.0249 2.16% < 0.05 1.38 0.0893 6.46% < 0.05 
Cit 1.09 0.0282 2.58% < 0.05 1.67 0.0503 3.00% < 0.05 
Met 1.08 0.0465 4.32% < 0.05 1.43 0.0214 1.49% < 0.05 
 56 
analytes except C6, C8, C10, C16 and C18, indicating that matrix does affect the response 
factors.  In addition, the response factors for most analytes and internal standards are 
significantly different from one using a two tailed t-test (p < 0.05).  Overall, the response factors 
for external samples appear to be very consistent with %RSDs less than 6.69%; however, 
response factors for extracted samples are much more inconsistent with %RSDs as high as 
16.7% for some analytes.  Since the responses are not equal for analytes and internal standards, 
concentrations of analytes would not be proportional to the internal standard at the same 
concentration, thus resulting in values that are lower or higher than the actual concentration in 
the sample.  Further, if the slope of the analyte response versus concentration is significantly 
steeper than that of the internal standard, then small changes in analyte concentration may 
result in relatively large quantification errors.  Therefore, when samples are analyzed by flow 
injection analysis using only response factors, there is a deviation from the actual value when 
analyte response factors are different from their internal standard.   For instance, the response 
factor for C5 was determined to be 1.27 so the calculated concentration is 21.3% lower than 
the actual concentration.  This indicates that using the concentration of the internal standard 
has the potential to inaccurately quantify analytes when the response factors are significantly 
different from one.   
2.3.2  Flow injection analysis ionization suppression evaluation 
One major problem reported with electrospray ionization is matrix related ionization 
suppression (Matuszewski, Constanzer, & Chavez-Eng, 2003; Trufelli et al., 2011).  As shown 
previously, the response factors for external samples are different from extracted samples, 
which is a result of competing ionization between the analytes and other components found in 
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the extracted sample.  When analyzing samples by flow injection analysis there is no separation 
between matrix components and the analytes. In addition analytes at higher concentrations 
compete for ionization with other analytes reducing their response which could potentially 
cause an analyte to be undetected.  Using labeled internal standards reduces problems with 
quantification related to matrix effects; however sensitivity can be dramatically affected 
(Trufelli et al., 2011).     
In order to evaluate ionization suppression or enhancement, a post injection infusion 
experiment for acylcarnitines and amino acids was conducted using a standard technique 
(Matuszewski et al., 2003; Trufelli et al., 2011).  First a sample was injected into the mobile 
phase flow without post column infusion to determine the lag time between the injection and 
the start of the sample plug and to determine time duration of the flow injection profile.  The 
lag time is related to the flow rate and dead volume of the system, which is dependent on the 
tubing length and the tubing diameter.  The flow injection profile of the sample appears as a 
broad peak since there is not any chromatographic separation.  After determining the profile 
for the flow injection analysis; matrix effects could be evaluated by infusing an external 
standard containing acylcarnitines and amino acids labeled internal standards(20 µL/min), at a 
200-fold dilution of the stock solution, in the flow path to the mass spectrometer prior to the 
electrospray source.  This provides an elevated baseline response for transitions associated 
with each labeled internal standard.   The labeled internal standards were used to assess matrix 
effects, since all blood samples will contain endogenous levels of amino acids and acylcarnitines 
which could artificially elevate or suppress the baseline.  Next, dried blood spot sample 
extracted in methanol with 0.1% formic acid without internal standard are injected onto the 
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system.  Shifts in the baseline would indicate regions of ion suppression (a negative response 
shift) or ion enhancement (a positive shift in the baseline).    Matrix effects were evaluated for 
six donor blood samples containing endogenous levels of acylcarnitines and amino acids and at 
3 fortified levels.  To quantify the degree of ion suppression, the average internal standard 
responses were evaluated during the flow injection profile and compared to the average 
internal standard response obtained by direct infusion with mobile phase. 
A representative extracted unfortified sodium heparin human dried blood spot sample 
analyzed by flow injection without infusion of internal standard solution is shown in Figure 
2.3A. This represents the flow injection profile for a typical sample.  A representative extracted 
unfortified sodium heparin human dried blood sample analyzed by flow injection with infusion 
of internal standard solution is shown in Figure 2.3B.  It is apparent from this experiment that 
there is a dramatic decrease in ionization during the time that the plug of sample is being 
analyzed. The overall decrease in ionization was calculated for each analyte at 4 different levels 
in triplicate and average overall suppression was determined to be 63%. For some analytes the 
matrix suppression was as high as 78% which could dramatically affect the detectability of 
analytes by flow injection resulting in potential misidentification of a metabolism disorder.  In 
order to reduce this matrix effect and improve sensitivity of this analysis, some form of 
chromatographic separation or sample clean-up is necessary.  
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Figure 2.3:  TIC of a precursor ion scan for production of 85 m/z, by flow injection analysis of 
extracted dried blood spots, A – Flow injection analysis of an unfortified sodium heparin 
blood sample without infusion of internal standards, B – Flow injection analysis of a 
unfortified sodium heparin blood sample with infusion at 20 µL/min of labeled internal 
standards solutions at a 200-fold dilution to assess matrix effects 
 
2.3.3 Chromatographic separation of amino acids and acylcarnitines 
Preliminary investigations involved optimization of chromatographic conditions to 
achieve acceptable retention of all analytes in a 3.1 minute total injection cycle time.  Mobile 
phase A contained water with 0.1% formic acid and mobile phase B contained a mixture of 90% 
acetonitrile and 10% water, such that the final buffer concentration was 10 mM ammonium 
formate.  A gradient elution was employed from 96% mobile phase B to 55% mobile phase B 
over 1.65 minutes (Table 2.3).  An Acquity UPLC pump was used to control the mobile phase 
flow at 0.3 mL/min and mobile phase composition allowing for the gradient elution of analytes.   
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        TIC   
Time (min) 
       0.12         0.24        0.36        0.48        0.60        0.72        0.84        0.96        1.08       1.20        1.32 
 
      0.12         0.24        0.36        0.48        0.60        0.72        0.84        0.96        1.08       1.20        1.32 
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Representative chromatograms of a single injection of an extracted sample using this gradient 
elution is presented in Figure 2.4.  Scheduled MRMs were set based on the retention times of 
the analytes and then allowing for 0.2 min retention time shift in either direction.  Acceptable 
separation of the isomers leucine, isoleucine and hydroxyproline was achieved; however C4 and 
C5 isomers were not separated under these conditions.    
 
Table 2.3: Chromatographic conditions for separation of acylcarnitines and amino acids 
Time (min) Flow Rate (mL/min) % A % B 
Initial 0.30 4 96 
1.65 0.30 45 55 
1.66 0.30 4 96 
3.10  End   
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Legend: A: C18, B:C16, C:C14, D:C12, E:C10, F:C8, G:C6, H:C5, I:C4, J: Phenylalanine, K: (1)Leucine, 
(2)Isoleucine, (3) Hydroxyproline, L:C3, M:Methionine, N:Tyrosine, O:C2, P:Valline, Q:Carnitne, 
R:Citrulline 
Figure 2.4: Chromatographic separation of 12 acylcarnitines and 8 amino acids with using 
gradient conditions shown in Table 2.3 and scheduled MRM transitions for each analyte 
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2.3.4  Chromatographic separation of C4 and C5 isomers 
Additional work was conducted to resolve the C4 and C5 isomers, since we were 
unsuccessful in achieving separation on the HILIC Amide column alone.  Several different chiral 
stationary phases were evaluated to improve this separation; however the cyclodextrin phases 
provided the best resolution.  Cyclodextrin phases provide unique selectivity in which 
interaction is based on inclusion complexation (Singh et al., 2010). Therefore, smaller analytes 
with less steric hindrance will form a more stable complex with the cyclodextrin, whereas larger 
analytes with more steric hindrance will not complex as strongly. 
Separation of the C4 and C5 isomers was optimized using the Astec cyclodextrin guard 
column.  The percent aqueous was varied from 0 to 10% and with buffer solutions prepared at 
a basic pH and an acidic pH.  The resolution between each isobar was determined for each 
condition using an external standard containing the individual isobars.  Figures 2.5 and 2.6 
shows the resolution that was determined for each condition for C4 and C5 isomers 
respectively.  It was apparent that 2-4% mobile phase A provided the best resolution and a 
buffer prepared at pH 8.7 was better than a buffer at pH 4.5.   The best resolution obtained for 
C4 isobars was 0.38 which is not sufficient for baseline resolution.  The resolution achieved for 
C5 isobars was 0.8 which was better but still not sufficient for baseline resolution.  Longer guard 
columns could be used however this would increase the analysis time making it impractical for 
a rapid second-tier test.  Better resolution may have been achievable with smaller particles or 
with alpha cyclodextrin instead of the beta cyclodextrin, however these columns are not 
commercially available.  Therefore it was decided to use the optimized conditions obtained 
with the current configuration for the additional research. 
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Figure 2.5:  Plot of resolution versus % mobile phase A, evaluated for separation of C4 
isomers on an Astec CYCLOBOND™ I 2000 guard column using isocratic elution at different 
percentages of mobile phase A and with mobile phase B prepared at pH 8.7 and pH 4.5  
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Figure 2.6:  Plot of resolution versus % mobile phase A, evaluated for separation of C5 
isomers on an Astec CYCLOBOND™ I 2000 guard column using isocratic elution at different 
percentages of mobile phase A and with mobile phase B prepared at pH 8.7 and pH 4.5   
 
Combining the cyclodextrin phase and HILIC Amide phase provides resolution of 0.83 for 
the C5 isobars and a resolution of 0.97 for the C4 isobars.  Baseline resolution is defined as a 
resolution of 1.5, however a resolution of 1 is acceptable for quantitative analysis (Miller, 
2005).   The same mobile phase was used for this separation as used for the separation in the 
first part with a modified gradient from 0% to 5% mobile phase A over 10 minutes with a flow 
rate of 0.3 mL/min.  The chromatographic separation of C4 and C5 isomers in an extracted 
sample that contains butyrylcarnitine, isobutyrylcarnitine, valerylcarnitine and 
isovalerylcarnitine is shown in Figure 2.7.  Although baseline resolution was not achieved, the 
separation described would allow identification and quantification of the analytes.  As stated 
previously, longer columns could be used to achieve full resolution of these isomers; however 
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the run time would be significantly longer. It was decided to employ the current separation, 
because a longer analysis time would not be desirable for a rapid second-tier test. Separation of 
these isomers allows for differential diagnosis for short chain acyl-coenzyme A dehydrogenase 
deficiency (SCAD) and isobutyryl-CoA dehydrogenase deficiency(IBCD) or isovaleric academia 
(IVA), which is not possible with flow injection analysis.    
 
Legend: A:ISO C5, B:C5, C:ISO C4,D:C4.  
 
Figure 2.7: Chromatographic separation of an extracted dried blood spot sample containing 
butylcarnitine (C4) and isobutyrylcarnitine (ISO C4) at 1.2 µmol/L and valerylcarnitine (C5), 
isovalerylcarnitine (ISO C5) at 0.96 µmol/L using modified gradient conditions with HILIC 
Amide and Astec CYCLOBOND™ I 2000 guard column 
 
2.3.5  Extraction optimization 
An extraction optimization experiment was conducted in which samples were extracted 
using various concentrations of methanol and water containing 0.1% formic acid.  Additional 
TIC 
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experiments were performed using acetonitrile and water containing 0.1% formic acid, and 
acetonitrile and water containing 10 mM ammonium acetate.  A 3.1 mm spot was punched 
from a control sample and extracted in 100 µL of each extraction solution.  Three replicates 
were analyzed for each extraction solution evaluated.  The samples were injected using the 
chromatographic conditions described earlier.  The response ratios with internal standard were 
plotted for each analyte and extraction condition, typical extraction profile curves for 
acetylcarnitine (C2), palmitoylcarnitine (C16) and phenylalanine (Phe) using methanol 
containing 0.1% formic acid are shown in Figure 2.8.  The extraction profiles for all the other 
analytes are very similar to these three profiles and are therefore not presented. From these 
plots it is apparent that 100% methanol with 0.1% formic acid demonstrated the highest 
recovery as compared to the other conditions tested and is a common extraction solution used 
for flow injection analysis (Chace, 2001; Chace, 2007). Although there was not a significant 
difference between some of the other extraction solutions, it was observed that more aqueous 
in the extraction solution caused the samples to appear cloudy.  The samples extracted in 
acetonitrile mixtures were visibly clearer than the samples extracted with methanol mixtures; 
however 20% aqueous is required in order to achieve comparable recovery to 100% methanol 
containing 0.1% formic acid.  Since methanol containing 0.1% formic acid is commonly used in 
newborn screening analysis, we elected to employ this solvent for further investigations. 
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Legend: C2-blue diamonds, C16-red squares, phenylalanine-green triangles. Values for phenylalanine 
were multipled x2 for graphical purposes. Error bars represent 1 standard deviation for 3 replicates. 
 
Figure 2.8: Plot of response versus % organic to show extraction efficiency of C2, C16 and 
phenylalanine from dried blood spots, sample were extracted in different percentages of 
methanol and water containing 0.1% formic acid (n=3) and analyzed using 3.1 minute 
chromatographic separation and scheduled MRMs   
 
2.3.6  Ionization suppression evaluation for chromatographic separation 
Ionization suppression was also evaluated for the chromatographic separation using the 
same technique as described earlier.  As discussed earlier it is difficult to assess matrix affects 
for samples that contain endogenous levels of the analytes of interest.  Therefore the labeled 
internals were used to assess matrix effects.  Dried blood spot samples were extracted in 100 
µL of methanol containing 0.1% formic acid and injected using the chromatographic conditions 
that were described in section 2.3.3.   In order to evaluate matrix effects the labeled internal 
standards were infused post column creating an elevated baseline.  While it was apparent that 
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some regions in the chromatogram showed some ionization suppression, the complexity of the 
chromatogram makes it difficult to quantify the degree of matrix suppression using this 
approach. Therefore, an additional experiment was conducted by comparing internal standard 
responses in extracted samples to external samples.  This experiment was performed for dried 
blood spots prepared from six different individuals.  Dried blood spot samples were extracted in 
triplicate for each individual using an internal standard working solution prepared in methanol 
containing 0.1% formic acid.  The samples were transferred to a clean 96-well plate and 
injected onto the LC/MS/MS system. The responses for the internal standard in extracted 
samples were compared to injections of the working internal standard solution.  The results for 
this experiment showed minimal matrix effects based on the percent differences in responses 
of the internal standards in extracted and external samples, shown in Figure 2.9.  Overall there 
was less than 20% matrix suppression observed for all the compounds except C16 which 
showed ionization suppression of 21.5%. All analytes demonstrated less than 5% relative 
standard deviations from triplicate analysis of 6 different lots of sodium heparin human whole 
blood samples.  This is a dramatic improvement over the flow injection analysis in which as 
much as 63% ion suppression was observed.  There was also a significant improvement for the 
relative standard deviation for this chromatographic analysis compared to the flow injection 
approach, which could further improve the positive predictive value (PPV) for metabolism 
disorders associated with elevated levels amino acids and acylcarnitines. 
 
  
Legend: Black bars are extracted samples white bars are external standards.  Error bars represent 1 standard deviation. 
Figure 2.9: Bar graph to show matrix suppression evaluated by comparison of internal standard responses in external 
standards with extracted dried blood spot samples, samples analyzed in triplicate using 3.1 minute chromatographic 
separation and scheduled MRMs
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2.3.7  Validation of analysis with chromatographic separation 
Validation of the chromatographic method included precision and accuracy, linearity 
and recovery.  Three replicate samples were analyzed on three separate days in order to assess 
inter assay precision and accuracy.  Prior to validation six different lots of sodium heparin 
human whole blood were analyzed to select a matrix that contained the lowest endogenous 
levels of analytes and to ensure the levels of analytes were below the reported cut-off values 
(McHugh et al., 2011) . The endogenous levels of all analytes were determined using the 
method of standard addition to create a four point curve from the amount fortified versus the 
response ratios obtained.  Acceptable linearity with correlation coefficients greater than 0.9950 
were observed for all analytes using linear regression.  From the linear regression y = mx + b, 
where “y” is the analyte response ratio, “x” is the analyte concentration, “m” is the slope and  
“b” is equal to the y-intercept.  Using this equation, the concentration in the unfortified sample 
can be obtained at the x-intercept where y = 0, x = -b/m.   After establishing concentration in 
the blank sample the calibration range for each analyte was established by adding the amount 
fortified to the blank concentration producing a six point calibration curve.   A larger range was 
used for calibration curves to allow for quantification above and below the targeted cut-off 
values for each analyte.  Different regression models and weighting factors were assessed for 
each analyte and the best model was chosen based on having the best correlation coefficient 
and lowest average percent difference from theoretical. After evaluating multiple models it was 
determined that a quadratic fit model with a 1/concentration weighting factor provided the 
best results for all analytes.  The final calibration range based on the adjusted concentrations is 
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shown in Table 2.4.  Correlation coefficients for all runs were greater than 0.9950 for all 
analytes.  
Table 2.4: Calibration range with average correlation coefficients from 3 days   
 Calibration Range  
(µmol/L) 
Average Correlation  
Coefficient 
 
C0 36.4 – 636 0.9990  
C2 16.7 – 257 0.9993  
C3 1.28 – 41.3 0.9989  
C4 0.210 – 10.2 0.9994  
C5 0.160 – 8.16 0.9988  
C6 0.048 – 8.05 0.9982  
C8 0.090 – 8.09 0.9967  
C10 0.090 – 8.09 0.9965  
C12 0.055 – 10.1 0.9968  
C14 0.052 – 8.052 0.9958  
C16 0.076 – 40.8 0.9954  
C18 0.570 – 16.6 0.9951  
Phe 91.3 -1291 0.9973  
Leu 115 – 715 0.9952  
Ile 64.4 -664 0.9982  
Tyr 61.4 -1261 0.9971  
Val 180 -1180 0.9980  
Cit 42.8 -443 0.9966  
Met 15.1 -615 0.9973  
 
The precision and accuracy for all the analysis of acylcarnitines and amino acids 
extracted from dried blood spots were calculated at each of the four concentrations in triplicate 
over 3 separate days, the precision was within 9,98% and the accuracy ranged from 85.7% to 
108%, as shown in Table 2.5.   However, the highest quality control sample for acetylcarnitine 
had an accuracy of 78.2%, which is outside the acceptable limit of + 15% based on FDA 
guidance for bioanalytical method validation.  The overall average accuracy was evaluated for 
each analyte by averaging the results from the 4 levels reported in Table 2.5 and is plotted in 
Figure 2.10.    
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Table 2.5: Precision and accuracy over three days using chromatographic separation and 
MRM transitions  
 
Level 1  Level 2  Level 3  Level 4 
 
Mean 
(µmol/L) %RSD 
 Mean 
(µmol/L) %RSD 
 Mean 
(µmol/L) %RSD 
 Mean 
(µmol/L) %RSD 
C0 59.4 (101) 3.10%  87.1 (99.6) 2.97%  240 (104) 3.03%  545 (105) 3.25% 
C2 23.7 (98) 9.85%  33.7 (93.4) 7.89%  86.0 (89.5) 7.97%  169 (78.2) 5.05% 
C3 2.50 (103) 10.9%  4.14 (98.3) 7.39%  12.7 (95.8) 4.83%  28.0 (89.6) 2.91% 
C4 0.529 (103) 8.90%  0.934 (97.2) 3.42%  3.08 (95.8) 3.19%  7.20 (93.4) 4.23% 
C5 0.412 (104) 8.48%  0.747 (98.9) 4.51%  2.47 (96.8) 2.65%  5.81 (94.4) 3.40% 
C6 0.291 (99.8) 2.16%  0.617 (94.7) 0.29%  2.34 (95.4) 2.69%  5.77 (95.3) 2.17% 
C8 0.333 (97.2) 6.00%  0.654 (93.0) 4.64%  2.47 (98.7) 2.92%  5.97 (97.8) 3.68% 
C10 0.338 (95.3) 7.14%  0.658 (92.2) 3.64%  2.41 (95.9) 3.50%  6.06 (99.1) 3.36% 
C12 0.335 (93.9) 3.62%  0.740 (91.4) 2.25%  3.07 (100) 2.07%  7.80 (103) 0.964% 
C14 0.283 (91.4) 8.72%  0.604 (90.2) 3.35%  2.43 (98.4) 3.51%  6.18 (102) 1.57% 
C16 2.43 (94.7) 13.1%  4.17 (88.4) 7.35%  15.2 (97.8) 1.53%  38.2 (103) 1.48% 
C18 1.23 (97.1) 13.2%  1.78 (89.4) 8.43%  5.64 (101) 4.73%  13.3 (104) 2.48% 
Phe 123 (98.9) 6.38%  170 (96.3) 5.62%  426 (97.7) 3.45%  903 (94.6) 4.89% 
Leu 130 (99.3) 3.47%  151 (96.4) 2.25%  272 (95.2) 1.75%  513 (94.1) 3.87% 
Ile 86.7 (101) 5.91%  111(98.8) 5.10%  233 (96.4) 2.46%  498 (99.4) 4.91% 
Tyr 124 (97.6) 4.35%  213 (97.3) 8.84%  719 (108) 5.90%  1614 (103) 2.50% 
Val 233 (99.6) 7.38%  270 (97.3) 9.07%  488 (98.9) 6.22%  877 (94.7) 5.83% 
Cit 51.1 (100) 6.77%  66.7 (97.7) 4.48%  154 (99.8) 3.09%  320 (97.6) 2.96% 
Met 31.3 (91.6) 4.98%  51.5 (85.7) 3.79%  197 (104) 5.03%  473 (105) 7.80% 
3 replicates for each level on 3 days (n=9). Percent (%) of target values indicated in parentheses  
  
 
Legend: Error bars represent 1 standard deviation for the average of the 4 different levels 
Figure 2.10: Bar graph for overall average accuracy determined for 12 acylcarnitines and 7 amino acids at 4 levels over three 
days, dried blood spots analyzed with 3.1 minute chromatographic separation and scheduled MRM transitions for each 
analyte 
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2.4  Conclusions 
In conclusion, a high speed separation for quantification of twelve acylcarnitines and seven 
amino acids using the same extracted sample that is analyzed with the non-derivatized 
newborn screening method was developed.  The method was validated with respect to 
linearity, precision and accuracy and recovery.  Matrix related ionization suppression evaluated 
by post column infusion showed less that and average of 8.24% difference in the response of 
the labeled internal standards when comparing the response in extracted dried blood spots to 
the response in external standards.  However, the responses for C14-d9, C16-d3 and valine-d8 
were approximately a 20% lower in extracted samples compared to external standards.  Overall 
the matrix suppression was dramatically better with the chromatographic separation than for 
the flow injection analysis method.  Furthermore, the chromatographic separation allows for 
assessment of MSUD by separating leucine, isoleucine and hydroxyproline.  Alternative 
chromatographic conditions can be used to adequately resolve C4 and C5 isomers allowing for 
differential identification of additional disorders SCAD, IVA IBMC, which is not possible in the 
current newborn screening methods.  The overall chromatographic separation can be 
conducted in approximately the same time frame as the established flow injection analysis and 
with the same sample, eliminating the need for additional sample preparation or 
instrumentation (Sweetman, 2001).  This method is a major improvement over the current 
newborn screening method allowing for differentially diagnoses of multiple disorders and 
improved quantification by resolving matrix related interferences.  In addition, our method 
does not require derivatization of samples and the injection cycle time is approximately the 
same as for the flow injection analysis.   
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CHAPTER 3 
 
DIRECT ANALYSIS OF DRIED BLOOD SPOTS BY IN-LINE DESORPTION 
COMBINED WITH HIGH RESOLUTION CHROMATOGRAPHY AND MASS 
SPECTROMETRY FOR QUANTIFICATION OF MAPLE SYRUP URINE 
DISEASE BIOMARKERS LEUCINE AND ISOLEUCINE  
 
Drawn from manuscript published in Analytical and Bioanalytical Chemistry 400(2011) 237-244.  
 
3.1  Introduction 
Direct analysis of dried blood spots (DBS) for newborn screening (NBS) could 
significantly improve the efficiencies of screening laboratories, allowing for reduced sample 
handling, decreased material costs and faster analysis.  Further, there is the potential for linking 
the data analysis directly to the patient, improving data integrity by minimizing any errors 
associated with improper sample identification and handling.  During our research, devices 
based on different technology for automated DBS analysis have been proposed and are now 
past the prototype stage (Abu-Rabie & Spooner, 2009; Déglon et al., 2011).  In addition, Leap 
Technologies has recently released an automated device which allows for in-line desorption of 
dried blood spots,  similar to the device that we published; however we are not aware of any 
studies that have been published using their device.  The Leap Technologies device is similar to 
our device in that the DBS card is placed in-line with the mobile phase flow from a HPLC system, 
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allowing for desorption of analytes from the DBS followed by chromatographic separation.  
Other work has shown that direct analysis of DBS is sensitive and practical for analysis of drugs 
and their metabolites for clinical pharmacokinetic studies (Déglon et al., 2011; Thomas et al., 
2010; Abu-Rabie & Spooner, 2009; Van Berkel & Kertesz, 2009), however they still require the 
addition of internal standard (IS) either into the sample matrix prior to analysis or require a 
predetermined disk to be punched from the filter paper card.  Other direct sampling 
approaches have been reported including the analysis of  DBS on filter paper by desorption 
electrospray ionization (DESI) (Takáts, Wiseman, & Cooks, 2005) or the analysis of biological 
fluids  on glass rods by direct analysis in real time (DART) (Cody, Laramee, & Durst, 2005), but 
both lack the ability to separate isomers and avoid matrix effects since no chromatographic 
separation is involved.  To date there has been no reported applications using direct sampling 
with chromatographic separation for biomarker analysis related to metabolism disorders.       
NBS for metabolism disorders has involved the analysis of DBS for nearly 50 years, a 
sample collection technique originally proposed by Robert Guthrie for the analysis of 
phenylalanine to identify newborns that suffered from phenylketonuria (Guthrie & Susi, 1963).  
Currently more than 50 different disorders can be identified from a NBS card including 
metabolism disorders, endocrinopathies, hemoglobinopathies and infectious diseases (Sahai & 
Marsden, 2009).  Within the first week of life, all newborns have blood collected by a heel prick 
and spotted on special filter paper cards.  These cards are dried and then shipped to NBS 
laboratories for testing.  This sample collection technique offers some distinct advantages 
including minimal sample collection volume and reduced costs associated with shipping and 
storage; it is less invasive than collecting venous samples and minimizes risks associated with 
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transmission of some infectious diseases such as HIV (Li & Tse, 2010; Parker & Cubitt, 1999).  
Depending on birthrate, a NBS laboratory receives between 350-1500 samples per day and due 
to the time sensitive nature of some of these disorders, they must report results as soon as 
possible (Chace, 2009).  Due to the large workload there is need for automated techniques and 
rapid screening methods to quickly identify affected children.   
Although the NBS methods for amino acids and acylcarnitines have proven to be 
acceptable for identification of several metabolism disorders, there have been reports of a high 
number of false positives results (Sahai & Marsden, 2009), additional confirmation testing 
required (Matern et al., 2007) and an inability to differentially identify certain disorders (Chace 
et al., 2003).  The widely used analysis of acylcarnitines and amino acids employs an extraction 
with butyl esterification followed by flow injection LC/MS/MS analysis.  Even though this 
technique allows for rapid screening, it lacks the ability to differentiate isobaric biomarkers 
(Sweetman, 2001; Matern et al., 2007; Bennett, 2009).  Maple Syrup Urine Disease (MSUD), a 
condition that results in the accumulation of branched-chain amino acids, is often misdiagnosed 
by newborns screening method since leucine, isoleucine and hydroxyproline are unresolved 
and a second-tier test is required for confirmation of this specific disorder (Matern et al., 2007). 
It has been reported that nearly 0.1% of all NBS samples have elevated levels of 
leucine/isoleucine/hydroxyproline and require additional testing for proper diagnosis (Matern 
et al., 2007).  Amino acid analysis typically involves some form of derivatization and 
chromatographic separation to resolve these isobaric species by either HPLC UV (Fekkes, 1996; 
Pappa-Louisi, Nikitas, Agrafiotou, & Papageorgiou, 2007), UPLC/MS (Boogers, Plugge, 
Stokkermans, & Duchateau, 2008), CE-MS (Soga, Kakazu, Robert, Tomita, & Nishioka, 2004) or 
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GC/MS (Kaspar, Dettmer, Gronwald, & Oefner, 2008), thus requiring the need for additional 
instrumentation, operators and costly consumables.     
We have developed a rapid in-line analysis of dried blood spots using a novel device 
coupled with a HILIC Amide chromatographic separation that is capable of resolving leucine, 
isoleucine and hydroxyproline in a 5 minute total analysis time.  Direct analysis is performed 
without any offline sample preparation, eliminating the need to punch disks from the filter 
paper card or adding internal standard to the dried blood spot.  HILIC Amide is a polar 
stationary phase with an amide functional group bonded to the silica that allows for better 
retention of hydrophilic species than conventional reverse phase columns.  This 
chromatographic separation eliminates the need for derivatization to resolve these isomers and 
mass spectrometry detection provides enhanced selectivity over HPLC UV and HPLC FLD.  Our 
technique allows for the assessment of MSUD by direct analysis of the original dried blood spot, 
reducing analysis time and eliminates the need for collection of additional samples from the 
newborn.  Further, this methodology shows the ability to directly analyze dried blood spots for 
quantification of biomarkers related to metabolism disorders, an advancement that could 
greatly improve the efficiencies of newborn screening. 
3.2  Materials and methods 
3.2.1  Materials and reagents  
Amino Acid Reference Standard, 1 nmol/µL in 0.1 N HCl was purchased from Agilent 
Technologies (Santa Clara CA, USA). Stable isotope labeled amino acid reference material was 
obtained from Cambridge Isotopes (Andover, MA, USA). Hydroxproline was obtained from 
ARCOS Organics (Morris Plains, NJ, USA).  HPLC grade acetonitrile, formic acid and ammonium 
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formate were from Fisher Scientific (Pittsburgh, PA, USA). Dye solution part # 716000765-1 was 
obtained from Waters Corp. (Milford, MA, USA). Control human sodium heparin whole blood 
was obtained from Biochemed (Winchester, VA, USA).  Newborn screening cards, 903 Protein 
Saver, were obtained from Whatman (Piscataway, NJ, USA).  A 22 Multiple Syringe Pump from 
Harvard Apparatus (Holliston, MA, USA) and a 250 µL Hamilton gas tight syringe from Fisher 
Scientific (Pittsburgh, PA, USA) was used for infusion tests.   Digital images and measurements 
for seal integrity evaluation were made with a VHX Digital microscope from Keyence (Itasca, IL 
USA).  
 
3.2.2  Chromatographic and instrumentation 
Chromatographic separations were conducted with a Waters Acquity HILIC Amide 
column (2.1 x 100 mm, 1.7 µm) Waters Corp., (Milford, MA, USA).  A Waters Acquity UPLC 
pump and sample manager were used for analysis for gradient separation and for controlling a 
Rheodyne, 2 position 10-port switching valve purchased from Analytical Sales (Pompton Plains 
NJ, USA).   The prototype direct sampling device was machined to hold two end caps from a 
pre-column filter holder and two 0.5 µm frits from Chrom Tech Inc. (Apple Valley, MN, USA). 
End caps were tightened using a Proto 6169A dial torque wrench from Stanley Proto Industrial 
Tools (Conyers, GA, USA). 
    
3.2.3  Mass spectrometry conditions 
A Waters Premier triple quadrupole mass spectrometer (Milford, MA, USA) equipped 
with an electrospray ionization (ESI) source in the positive ion mode was used.  Optimization of 
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the instrument parameters including desolvation temperature, source temperature, 
desolvation gas flow, cone gas flow, capillary voltage, cone voltage and collision energy was 
performed by direct infusion of a solution containing leucine, isoleucine and leucine-d3.  
Optimal sensitivity was achieved using 4.0 kV for the capillary, 18.0 V for the cone, and 14 eV 
for the collision energy.  The desolvation temperature was 375 oC using nitrogen as the 
desolvation gas at a flow of 800 L/hr. Cone gas was nitrogen at a flow of 20 L/hr with a source 
temperature of 110 oC.  Argon was used for the collision gas at a flow of 0.2 L/hr. Multiple 
reaction monitoring (MRM) from 131.6 m/z to 85.75 m/z was used for leucine and isoleucine 
and 134.6 to 88.8 m/z was used for leucine-d3 internal standard.  A 0.1 second dwell time was 
used for each transition with a 0.02 second inter-scan delay for a total cycle time of 0.27 
seconds.     
 
3.2.4  Preparation of dried blood spots 
For the validation portion of this study, sodium heparin human whole blood was 
fortified at 3 levels (100 nmol/mL, 150 nmol/mL and 250 nmol/mL) using a 1.0 nmol/µL Amino 
Acid Reference Standard purchased from Agilent Technologies.  Fortified samples were 
prepared in volumetric flasks by diluting the appropriate volume of amino acid reference 
standard (1.0 nmol/µL) with whole blood and thoroughly mixed.  For the validation 55 µL of 
each fortified sample along with a blank was spotted onto Whatman, 903 Protein Saver 
newborn screening cards. Samples were allowed to dry at room temperature for 2 hours and 
stored at 0-5 oC prior to analysis.      
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3.3  Results and discussion 
3.3.1  Design of device 
This device allows for direct sampling of NBS cards without any offline preparation, 
eliminating the need to add internal standard or punching a predetermined-size disk from the 
dried blood spot.  Direct analysis of NBS cards would allow for sample identification to be 
directly linked to sample analysis via a bar code reader, with the bar code being on the card 
itself, minimizing identity errors associated with transfer of the punched out spot to a tube or 
well if the disks are removed from the screening card.  NBS cards are placed directly in the flow 
path of the liquid chromatograph eluent so that analytes can be desorbed from the card and 
chromatographically resolved on an analytical column.  The prototype device was machined to 
hold two in-line frit end caps such that they could be placed on either side of the newborn 
screening card and tightened, forming a leak free seal.  In addition this device allows for 
different diameter frits to be used so that the sample size could be varied if needed, however 
for our experiments we used a 1.5 mm x 0.5 µm frit.  Figure 3.1 shows the prototype device 
that was used.   
  
 83 
                                
Legend: A: two in-line frit end caps are used with 0.5 µm frits and a slit allows for screening cards to be 
placed in the flow path, B: Frit end-caps are tightened forming a leak free seal so that eluent can be used 
to elute analytes from the filter paper card 
Figure 3.1: Schematic of prototype in-line desorption device showing direct analysis of dried 
blood spots  
 
3.3.2  Seal integrity investigation 
Infusion of a dye solution through the device containing a blank card was used to assess 
the seal integrity of the device.  The end caps containing the in-line frits were tightened to 
various applied torques to determine how pressure influences the sealing attributes.  In 
addition we evaluated high and low concentrations of organic solvent in the solution to 
determine if there was any impact related to solvent viscosity.  A Harvard Apparatus syringe 
pump, with a 250 µL Hamilton gas tight syringe, was used to control the flow of the dye 
solution through the device.  The solution was infused through the device at a 100 µL/min flow 
rate with either a 30 second or 1 minute analysis to simulate the intended operation conditions.  
Dye solutions of 50% acetonitrile or 90% acetonitrile were evaluated.  End caps were tightened 
using a dial torque wrench at various torques from 30 to 60 in-lbs.  A torque of 30 in-lbs was the 
minimum torque that could be applied to firmly hold the card in place and a torque of 60 in-lbs 
    
A 
Mobile Phase 
B 
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was the maximum torque that could be applied without damaging the card from shearing 
forces.  Therefore, it was decided to use this range to evaluate the seal integrity of the device.  
A digital microscope was used to take measurements of the inside and outside diameters of the 
frit, along with the diameter of bleed that appeared on the filter paper.  Images shown in 
Figures 3.2A and 3.2B present the dimensions for the 0.5 µm in-line frit and images 3.2C and 
3.2D were obtained when infusing a 50% acetonitrile solution or a 90% acetonitrile solution, 
respectively.  Three replicates were analyzed under each condition at various torque settings, 
to evaluate reproducibility of this technique; data is plotted showing the bleed diameter for 
both dye solutions, Figure 3.3.  The measurements for the inner and outer diameters of the frit 
are represented by gray boundary lines shown on the graph.   
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Legend: A, B Digital microscope images of 0.5 µm inline frit used and representative images for a 
solution with C 50% acetonitrile and D 90% acetonitrile showing the bleed diameters obtained 
Figure 3.2: Digital microscopic images for 0.5 µm in-line frit and filter paper samples showing 
the bleed diameter for a dye solution containing either 50% acetonitrile or 90% acetonitrile 
infused at 100 µL/min for 1 minute 
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Legend: Top and bottom boundary lines in grey indicate the inside and outside diameter of the inline 
filter.  Error bars represent 1 S.D. from three replicates.  
Figure 3.3: Plot of the bleed diameter by direct infusion of a dye solution containing either 
50% acetonitrile or 90% acetonitrile through the in-line desorption device at 100 µL/min for 1 
minute 
 
 
ANOVA with a student t-test was used to compare the variances and means for the 
bleed diameters of each solution at the different applied torques. The results indicate that 
there is not a significant difference in bleed diameter for different applied torques; 90% 
acetonitrile p > 0.057 and 50% acetonitrile p > 0.2395.  The average bleed diameter observed 
for 50% acetonitrile solution was 3.13 mm and for the 90% acetonitrile solution it was 4.73 mm.  
Although the bleed diameter was larger for the solution containing 90% acetonitrile, all of the 
results were within the outside diameter of the frit indicating that a leak free seal was achieved.  
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In addition, the results showed acceptable reproducibility with relative standard deviations 
(RSD) less than 6.86% for all experiments except for the 50% acetonitrile at 50 in-lbs which 
demonstrated a RSD of 18.9%. The results indicate that an acceptable seal was achieved and no 
bleed exceeded the outside diameter of the frit with the values of torque studied.  Since the 
bleed was contained within the dimensions of the frit and did not disturb the remaining portion 
of the sample, multiple analyses can be performed from a single dried spot.   Based on the 6.6 
mm outside diameter of the frit and the 13 mm dried blood spots, three measurements can be 
made from a single dried blood spot.  In addition, the Whatman, 903 Protein Saver newborn 
screening cards appear to withstand the solvents used and do not deteriorate under these 
conditions. 
   
3.3.3  Elution profile for leucine and isoleucine from dried blood spots 
In order to determine the optimal elution conditions for leucine and isoleucine, by direct 
analysis of the DBS, various mixtures of eluent were evaluated using a flow rate of 0.1 mL/min.  
In addition, the elution solvent needed to be appropriately matched to the chromatographic 
separation, in order to achieve acceptable retention of leucine and isoleucine.  Hydrophilic 
interaction chromatography (HILIC) employs a polar stationary phase with a normal phase 
separation mechanism in which the aqueous mobile phase is the stronger elution solvent and 
the organic mobile phase is the weaker elution solvent.  Therefore, a higher concentration of 
aqueous will result in less retention of the analytes on the HILIC analytical column reducing the 
chromatographic performance of the column.  Optimal retention of compounds is achieved 
with organic concentration greater than 50%.  Mobile phase A contained 10 mM ammonium 
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formate with 0.1% formic acid and mobile phase B contained a mixture of 90% acetonitrile and 
10% water, such that the final buffer concentration was 10 mM ammonium formate.  For 
elution optimization, we evaluated various percentages of mobile phase A, the aqueous 
component, from 5% to 35% to determine elution profiles of leucine and isoleucine.  No 
chromatographic separation was used for this portion so that the elution profile could be 
analyzed independent of chromatographic performance.  The 2-position 10-port switching 
valve was switched to elute the analytes at 0.25 minutes and data was collected for 3 minutes 
using multiple reaction monitoring (MRM) of the 131.7 to 85.8 m/z, the specific mass transition 
for leucine and isoleucine. Figure 3.4 shows the elution profiles obtained under the various 
conditions tested.  
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Figure 3.4: Elution profiles for leucine and isoleucine from dried blood spots using in-line 
desorption device, mobile phase flow rate set to 0.1 mL/min and evaluated isocratic elution 
with 5%, 15% , 25% and 35% aqueous  
 
The plots indicate that the majority of the analytes elute within the first minute, from 
0.25 minutes to 1.25 minutes, under all elution solvents tested.  However, the plots show that 
some residual analyte continues to elute out past 3 minutes. Further evaluation of the profiles 
show differences in the absolute response varied between the elution solvents.  There are 
several possible factors that could contribute to these differences, such as solvent desorption 
strength, matrix suppression and ionization efficiency.  Overall the elution profiles appeared to 
be similar and only slight differences are seen in the residual level of analyte eluted after 3 
minutes.  Based on these results a one minute elution would be acceptable and additional 
elution time does not provide significant gains.  Further elution time impacts the loading 
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volume placed on the chromatographic column, increasing this volume can dramatically impact 
chromatographic performance and in order to minimize the overall analysis time the elution 
time should be as short as possible.      
3.3.4  Chromatographic optimization 
Preliminary investigations involved optimization of chromatographic conditions to 
achieve separation between leucine, isoleucine and hydroxyproline.  Mobile phase composition 
was the same as described above, but for this a gradient elution was employed from 90% 
mobile phase B to 75% mobile phase B over 1.6 minutes shown in Table 3.1.  An Acquity UPLC 
pump was used to control the mobile phase flow and mobile phase composition allowing for a 
gradient elution of analytes.   Resolution was assessed for the separation of leucine and 
isoleucine and was determined to be approximately 1.2.  Separation between two closely 
eluting peaks is determined to be acceptable when the resolution is greater than 1 (Miller, 
2005).    
Table 3.1: Initial Chromatographic conditions without in-line desorption device 
Time (min) Flow Rate 
(mL/min) 
% A % B 
Initial 0.35 10 90 
1.60 0.35 25 75 
2.70 0.35 25 75 
2.75 0.35 5 95 
 
The next step was to incorporate the on-line desorption device prior to the HILIC Amide 
separation to assess chromatographic performance for direct analysis of DBSs.  In order to 
include the desorption device the gradient was modified to include both the desired switching 
interval, elution time and ratios of mobile phase A and B.   The same gradient profile and slope 
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used to chromatographically elute the analytes was adjusted based on elution time either with 
a 30 or 60 second delay.   Three different elution conditions were evaluated to determine 
impact of elution time and aqueous concentration on chromatographic performance.  We 
evaluated a 30 second elution with 90% mobile phase B, a 60 second elution with 90% Mobile 
phase B and a 60 second elution with 95% mobile phase B; the results are shown in Figure 3.5.  
The resolution for the three conditions was evaluated and was determined to be 1.2 for both 
the 30 second elution and 90% mobile phase B and for 60 second elution and 95% mobile phase 
B.  The resolution was 1.1 for the 60 second elution and 90% mobile phase B elution.  Although 
acceptable resolution was achieved for a 30 second elution with 90% mobile phase B, the 
response was approximately 40% lower than with a 60 second elution time.  However, 
resolution between leucine and isoleucine was not as good with a 60 second elution with 90% 
mobile phase B.  The best resolution and response was obtained for a 60 second elution with 
95% mobile phase B, Table 3.2 shows the final gradient program used. 
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Legend: A: 30 second elution 90% mobile phase B; B: 60 Second elution 90% mobile phase B; C: 60 
second elution 95% mobile phase B 
Figure 3.5: Chromatographic separation on HILIC Amide column for leucine and isoleucine 
following in-line desorption from a dried blood spot using different elution times and solvent 
strengths  
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Table 3.2: Final chromatographic conditions with in-line desorption device 
Time (min) Flow Rate (mL/min) % A % B Valve Position Description 
Initial 0.1 5 95 1 Bi-pass 
0.04 0.1 5 95 2 Load 
1.05 0.1 5 95 1 Bi-pass 
1.08 0.35 5 95 1 Bi-pass 
2.50 0.35 20 80 1 Bi-pass 
3.70 0.35 20 80 1 Bi-pass 
3.75 0.35 5 95 1 Bi-pass 
 
 
For quantification of leucine and isoleucine an Acquity UPLC autosampler was used to 
inject the internal standard working solution which passed through the screening card at the 
same time as the analytes are eluted.  This timing was optimized by varying the initial switching 
time and evaluating the response of the internal standard.  The optimal switching time is based 
on the dead volume of the system.  The dead volume of the system is a measure of the system 
volume, which includes all the tubing, including the injection loop between the pump and the 
column.  This volume can vary dramatically from system to system depending on the pump 
type, mixing valves and injection loops.  As a hypothetical example; if the dead volume of the 
system was 1 mL and the flow rate was 1 mL/min then it would take approximately 1 minute 
for the mobile phase to go from the pump to the column.  However, if the dead volume was 2 
mL then it would take 2 minutes for the mobile phase to reach the column.  For our purposes 
we were concerned about the volume between the autosampler and the device, so we 
optimized the switching time so that the internal standard would reach the device at the same 
time as the valve was switched.  Systems with a larger dead volume will require additional time 
for the internal standard to reach the device and systems with a smaller dead volume will not 
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require as much time. This technique allows for quantification of leucine and isoleucine without 
pretreatment of the NBS card with internal standard.  For the analysis, 10 µL of internal 
standard working solution, 6.25 nmol/mL, was injected onto the LC/MS system allowing for 4 
times as many samples to be processed with the internal standard working solution compared 
to the current newborn screening method, resulting in significant cost savings. Figure 3.6 shows 
the final chromatographic separation employing the on-line desorption device and with elution 
using the internal standard.  The internal standard, Leucine-d3, elutes at approximately the 
same time as leucine. 
Legend: A: leucine-d3 at 3.42 min; B: leucine at 3.41 min, isoleucine at 3.53 min and 
hydroxyproline at 4.29 min. 
Figure 3.6: Final chromatographic separation for leucine, isoleucine, hydroxyproline and 
leucine-d3 using in-line desportion device and a HILIC Amide column  
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3.3.5  Validation of device for quantification of leucine and isoleucine 
Validation included both intra spot precision and accuracy, inter spot precision and 
accuracy, linearity, recovery and post column infusion for matrix suppression.  Three replicate 
samples were analyzed from a single spot across three separate days in order to assess intra 
spot precision and accuracy.  Inter spot precision was assessed by analyzing one replicate from 
3 different spots on a single day.  Since human whole blood contains endogenous levels of 
leucine and isoleucine, the concentration in the blank was determined first.  Quantification of 
the endogenous levels was performed using the method of standard addition to create a curve 
from the amount fortified versus the response ratios obtained, shown in Figure 3.7A.   
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Concentration (µmol/L) 
A 
B 
Concentration (µmol/L) 
Standard addition plot for leucine 
Standard addition plot for leucine with addition of endogenous level 
Legend: A: Plot based on amount fortified to blood, x-intercept is used to calculate endogenous level found in 
whole blood, B: Calculated concentration for a blank was used to determine concentration of fortified levels. Error 
bars represent 1 Standard deviation 
 
Figure 3.7: Standard addition plots for leucine generated by the analysis of dried blood spot  
samples fortified with leucine at three levels and without fortification in order to quantify  
the endogenous level present in samples, all samples analyzed in triplicate 
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Regression analysis was evaluated over three days using analyte response ratios with 
internal standard (leucine-d3).  The response ratios for the unfortified samples and samples 
fortified at three concentrations for leucine and isoleucine were plotted versus the fortified 
concentration.  Linear regression y = mx + b was used to determine the unfortified sample 
concentration,  where “y” is the analyte response ratio, “x” is the analyte concentration, “m” is 
the slope and  “b” is equal to the y-intercept.   The concentration in the unfortified sample can 
be obtained at the x-intercept where y = 0, x = -b/m.   Using this concentration we can then 
calculate the amount in each fortified level, for example level 1 would be 100 nmol/mL + blank 
concentration.  The data is then plotted using the calculated theoretical levels for the blank and 
each fortified level versus the response ratios, Figure 3.7B.  A linear regression was used with a 
weighing factor of 1/concentration and back calculated values are determined for each level.   
The final calibration range based on the adjusted concentrations were from 128 to 383 
nmol/mL for leucine and from 59.9 to 324 nmol/mL for isoleucine.  Correlation coefficients (r) 
for all runs were greater than 0.9805, except for one run the correlation coefficient was 0.9706 
for isoleucine.  Precision and accuracy were calculated for each calibration standard on three 
separate days for inter spot variability and on one day for intra spot variability.  Overall, intra 
spot precision ranged from 3.21% to 5.84% for leucine and 4.43% to 9.14% for isoleucine with 
accuracy of 92.3% to 105% for leucine and 90.9% to 108% for isoleucine (Table 3.3).  Inter spot 
precision ranged from 2.38% to 9.98% for leucine and 3.26% to 7.33% for isoleucine with 
accuracy of 89.7% to 107% for leucine and 88.0% to 110% for isoleucine (Table 3.4). 
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Table 3.3: Intra spot precision and accuracy for leucine and isoleucine determined by 3 
replicates analyzed on 3 different days 
  Blank Low Level Mid Level High Level 
Fortified Conc. 0 nmol/mL 100 nmol/mL 150 nmol/mL 250 nmol/mL 
Leucine     
Average Conc. (nmol/mL) 128 205 274 383 
Average Precision 5.84% 5.05% 3.21% 4.09% 
Average Accuracy 105% 92.3% 101% 104% 
      
Isoleucine     
Average Conc. (nmol/mL) 59.9 141 202 324 
Average Precision 9.14% 8.64% 6.17% 4.43% 
Average Accuracy 108% 90.9% 98.4% 106% 
 
Table 3.4: Inter spot precision and accuracy for leucine and isoleucine determined by 1 
replicate on 3 different spots analyzed on one day 
 Blank Low Level Mid Level High Level 
Fortified Conc. 0 nmol/mL 100 nmol/mL 150 nmol/mL 250 nmol/mL 
Leucine     
Average Conc. (nmol/mL) 128 198 275 383 
Average Precision 2.38% 9.98% 8.19% 6.46% 
Average Accuracy 107% 89.7% 102% 104% 
      
Isoleucine     
Average Conc. (nmol/mL) 67.8 142 208 333 
Average Precision 3.26% 7.33% 3.27% 7.21% 
Average Accuracy 110% 88.0% 98.3% 107% 
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Three replicates of a mid-level fortified sample were used to assess recovery. Recovery 
was performed by conducting six replicate injections from a single position on a DBS. The peak 
areas from each individual injection were summed to provide a total area eluted which was 
used as 100% recovery.  From this recovery of the first elution could be calculated.  Recovery 
was determined to be 63.6% for leucine and 65.7% for isoleucine with RSDs within 4.34%. 
3.3.6  Matrix suppression evaluated using a post-column infusion technique     
A post-column infusion experiment for leucine, isoleucine and leucine-d3 was 
conducted to evaluate ion suppression or enhancement due to the matrix (Matuszewski et al., 
2003).  A syringe pump was used to continuously infuse (10 µL/min) of an external solution 
containing 100 nmol/mL of leucine, isoleucine and leucine-d3 in the flow path to the mass 
spectrometer post column. This provided a high baseline response for transitions associated 
with each compound so that when matrix is eluted pre-column, ion suppression would appear 
as a negative response shift in this high baseline, whereas ion enhancement would appear as a 
positive shift. The time duration of these shifts indicate elution times where ion suppression 
and enhancement occur.  Blank matrix blood spots were eluted using the optimized 
chromatographic conditions while monitoring for shifts in the specific mass transitions for the 
analytes and internal standard.  Figure 3.8, shows a representative chromatogram of a sodium 
heparin human blood blank eluted using this post column infusion technique.  The initial 
negative shift seen at 1.07 minutes is attributed to a change in flow rate from 0.1 mL/min to 
0.35 mL/min.  This decrease in ionization is due to the increase in flow rate and should not 
impact the quantification of the analytes.  Additional suppression shifts in the chromatogram 
were observed throughout the separation for both the analytes and internal standard channels.  
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As previously discussed it is difficult to assess matrix affects in samples that contain 
endogenous levels of the analytes of interest.  In these dried blood spot samples, peaks for 
leucine and isoleucine were observed (Figure 3.8B) at the expected retentions for leucine and 
isoleucine, due to the endogenous levels in human whole blood.  Therefor the internal standard 
transition was used to assess matrix affects.  The greatest suppression is less than 20% of the 
total peak response for leucine and isoleucine.  
 
 
Legend: A: Mass transition for leucine-d3, internal standard 134.6 > 88.8. B: Mass transition for leucine 
(3.30 min) and isoleucine (3.41 min) 131.6 > 85.7.  Flow rate adjusted from 0.1 mL/min to 0.35 mL/min 
at 1.07 minutes resulting in a decrease in ionization. 
Figure 3.8: Matrix suppression evaluation for analysis of a dried blood spot sample using the 
in-line desportion device and chromatographic separation on the HILIC Amide column, post-
column infusion of leucine, isoleucine and internal standard at 100 nmol/mL   
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3.4 Conclusions 
In conclusion, direct analysis of dried blood spots using a prototype device was applied 
to the quantification of biomarkers for MSUD.  Work has been presented that shows that this 
device provides a leak free seal allowing for direct analysis of DBSs eliminating the need for any 
offline sample preparation.  The method was validated and provides good precision and 
accuracy for leucine from 128 to 383 nmol/mL and isoleucine from 59.9 to 324 nmol/mL 
appropriate concentration ranges for identification of MSUD.  Direct analysis provides several 
advantages over current second-tier tests for MSUD in that there is no need for derivatization, 
analysis can be done with the addition of the device to current instrumentation and direct 
analysis can be conducted with original dried blood spot.  This prototype design could be easily 
automated using conventional robotics, which would allow for hundreds of samples to be 
processed with minimal human intervention, greatly improving the efficiency of newborn 
screening.     
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CHAPTER 4 
 
A NOVEL ON-CARD APPROACH FOR DETERMINING HEMATOCRIT OF 
DRIED BLOOD SPOTS ALLOWING FOR CORRECTION OF SAMPLE 
VOLUME 
 
4.1  Introduction 
Analysis of dried blood spots has been used in newborn screening for decades and more 
recently it has become increasingly applied in bioanalytical analysis of pharmaceuticals for new 
drug development and for therapeutic drug monitoring  (Denniff & Spooner, 2010; Edelbroek et 
al., 2009; O'Mara, Hudson-Curtis, Olson, Yueh, Dunn, Spooner, 2011).  This sample collection 
technique offers many advantages including minimal sample collection volume, reduced costs 
associated with shipping and storage, it is less invasive than collecting venous samples and 
minimizes risks associated with transmission of some infectious diseases such as HIV (Li & Tse, 
2010; Parker & Cubitt, 1999) Despite the numerous advantages to this sample collection 
technique, the most common concern is how to correct for sample volume variations.  
Hematocrit, which is a measure of concentration of red blood cells per unit volume of blood, 
has the largest influence on the sample volume for dried blood spot analysis.  This is primarily 
due to the viscosity of blood being greater at high hematocrit and less at low hematocrit 
(Edelbroek et al., 2009).  When blood is applied to filter paper, the blood will diffuse at different 
rates for blood samples with low and high hematocrits affecting the size of the blood spot 
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(Adam et al., 2000; Denniff & Spooner, 2010; Edelbroek et al., 2009; Mei et al., 2001). Since a 
fixed punch size is used for sample analysis, the sample amount is dependent on hematocrit 
and it can be significantly different in cases of abnormally low and high hematocrit (Denniff & 
Spooner, 2010; Mei et al., 2001).  Typical hematocrit ranges from 28–67% in most healthy 
individuals and the normal range for newborns is from 42-64% (Denniff & Spooner, 2010). 
However, abnormal hematocrit can be characteristic of polycythemia or anemias, causing high 
and low hematocrit respectively. Several publications have reported the effects of hematocrit 
on concentration of pharmaceuticals (Denniff & Spooner, 2010; Wilhelm et al., 2009) and 
amino acids and acylcarnitines (Holub et al., 2006) in dried blood spots.  In addition, some 
compounds show a chromatographic effect, where the concentration of the analyte is higher in 
a center punch relative to a peripheral punch (Holub et al., 2006; O'Mara, Hudson-Curtis, 
Olson,Yueh, Dunn, Spooner, 2011).  Others have reported minimal differences in sample 
volume relative to normal hematocrit levels (Denniff & Spooner, 2010).  It is difficult to    
accurately quantify sample volume unless a predefined volume of blood is spotted on filter 
paper and the whole spot is analyzed.   Edelbroek has reviewed several publications using this 
technique which eliminates issues with hematocrit variations (Edelbroek et al., 2009).  Although 
this approach may work for clinical analysis or therapeutic drug monitoring, it is not practical 
for newborn screening. 
Newborn screening relies on a simplistic approach of spotting whole blood from a heal 
puncture on the filter paper and the sample volume is approximated at 3.1 µL from a 3 mm 
punch (Holub et al., 2006).  In most cases the identification of a specific disorder is fairly 
distinguishable however; there are times when correction for volume could mean the 
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difference between a test positive and a test negative result (Holub et al., 2006; Orsini et al., 
2010).  Routine DBS analysis has been shown to be acceptable for newborn screening for 
decades but, there is still the potential to further improve the positive predictive value of this 
test.  Since cut-off values are set independent of hematocrit the potential to misidentify 
samples is increased with high or low hematocrit samples.  It has been reported that sample 
volume in DBS analysis can vary by as much as 47% depending on the hematocrit (Mei et al., 
2001). A recent study evaluated the effect hematocrit has on the measured concentration of 
succinylacetone, which  showed that samples with low hematocrit quantitated approximately 
45% low and samples with high hematocrit quantitated 24% higher than expected (Peng, Liu, & 
Peng, 2012).  Hematocrit effects on the analysis of amino acids and acylcarnitnes, markers for 
organic acid disorders, amino acid disorders and fatty acid oxidation disorders has been 
reported (Holub et al., 2006). Holub showed a positive correlation between analyte 
concentration and hematocrit.  A chromatographic effect for some analytes showed significant 
differences in their concentration between peripheral and center punches (Holub et al., 2006).  
Attempts have been made to correct for differences in hematocrit using hemoglobin variant 
testing to approximate sample volume (Orsini et al., 2010) Orsini reported an average accuracy 
of 108% using this technique, however the results ranged from 73.5% to 142% (Orsini et al., 
2010).   
UV and NIR spectroscopy has been used for years to evaluate the composition and 
properties of blood in vitro and in vivo (Johns et al., 2001; Meinke et al., 2005; Schmitt et al., 
1986; Serebrennikova et al., 2008; Steinke & Shepherd, 1986; Steinke & Shepherd, 1988; Zhang 
et al., 2000; Zijlstra et al., 1991; Zonios & Dimou, 2006).  Several models and theories have been 
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used to explain the light scattering, absorption and reflectance properties of whole blood to 
determine hemoglobin concentration, hematocrit and blood oxygenation levels.  Many of these 
theoretical models have resulted in medical devices used by health care providers including 
oximeters (Schmitt et al., 1986; Steinke & Shepherd, 1986) and hemoglobinometers ( Zhang et 
al., 2000).  These devices offer several major advantages over other sampling techniques 
including: nondestructive analysis, less invasive sampling, portable instrumentation and faster 
analysis time.   
Analysis of whole blood in vivo and in vitro solutions has several complexities, due to 
the nature of the medium and other biological factors.  Several different models and theories 
have been used to explain the properties of blood either in vitro or in vivo.  Mie theory 
supports the light scattering properties of whole blood to evaluate red blood cell size and 
concentration in dilute solutions (Steinke & Shepherd, 1988).  Although there has been some 
criticism to using Mie theory due to the shape of the red blood cells not being spherical, 
experimental results were comparable the theoretical predictions.  Absorption measurements 
have been reported to be inversely proportional to reflectance of blood in thin films of non-
hemolyzed blood and reflectance increases with increasing the thickness of the film (Anderson 
and Sekelj, 1967).  The absorption properties of whole blood deviates from Beers law at high 
concentrations where the optical density does not appear to be related to hemoglobin 
concentration nor the path length (Lovell, Hebden, Goldstone, & Cope, 1999).  More recently a 
paper by Serebrennikova et. al. proposed a new theoretical model that uses diffuse reflectance 
and light scattering to analyze whole blood (Serebrennikova et al., 2008).  From their data it 
was apparent that reflectance is related to erythrocyte concentration.  Although there are 
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many spectroscopic methods used for hematocrit determination for whole blood in vivo and in 
vitro, there have not been any published articles related to the spectroscopic analysis of dried 
blood spots to determine hematocrit.        
We have developed a novel on card approach to evaluate hematocrit on dried blood 
spot using diffuse reflectance.  Our method is the first reporting using a direct sampling 
approach for hematocrit that shows improved precision and accuracy by correcting for sample 
volume.  Direct analysis by reflectance of can be used to relate sample hematocrit allowing for 
volume correction.  This technique could be used in newborn screening or clinical analysis 
improving the quantification of dried blood spot analysis.  Results are presented for 
quantitative analysis of acylcarnitines in dried blood spots from donor samples at various 
hematocrit levels.  Correcting for sample volume is increasingly important to properly identify 
children with low hematocrit or high hematocrit.      
4.2  Materials and methods 
4.2.1  Materials and reagents  
Acylcarnitine reference standards were purchased from VU Medical Center Metabolic 
Laboratory, (Amsterdam, The Netherlands). Stable isotope labeled acylcarnitines reference 
materials were obtained from Cambridge Isotopes (Andover, MA, USA). HPLC grade 
acetonitrile, formic acid and ammonium formate were from Fisher Scientific (Pittsburgh, PA, 
USA). Control human potassium EDTA whole blood was obtained from Biochemed (Winchester, 
VA, USA).  Newborn screening cards, 903 Protein Saver and DMPK filter paper cards were 
obtained from Whatman (Piscataway, NJ, USA).      
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4.2.2  Chromatographic  instrumentation 
Chromatographic separations were conducted with a Waters Acquity HILIC Amide 
column (2.1 x 50 mm, 1.7 µm) Waters Corp., (Milford, MA, USA).  A Waters Acquity UPLC pump 
and sample manager were used for analysis and gradient separation.  A Waters Premier triple 
quadrupole mass spectrometer (Milford, MA, USA) equipped with electrospray ionization (ESI) 
source in positive ion mode was used.  Instrument parameters were optimized for analysis of 
acylcarnitines and their labeled internal standards by direct infusion of an external solution into 
the mass spectrometer.  Optimal sensitivity was achieved using 3.8 kV for the capillary, 390 oC 
desolvation temperature with nitrogen as the desolvation gas at a flow of 800 L/hr. Cone gas 
was nitrogen at a flow of 20 L/hr with a source temperature of 110 oC.  Argon was used for the 
collision gas at a flow of 0.4 L/hr. Multiple reaction monitoring (MRM) was used for all analytes 
and internal standard.  Individual mass transitions for all analytes is shown in Table 4.1.  
Optimized MRMs were used based on the retention time of analytes to achieve a minimum 0.4 
minute window around each peak with a 0.02 second dwell time and a 0.02 second inter-scan 
delay.     
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Table 4.1: Acylcarnitines and amino acids analyzed and the mass spectral settings for MRM 
mode 
Analyte ID CV (V) CE (eV) 
MRM 
Transition 
I.S. 
I.S. MRM 
Transition 
Time segment 
(min) 
Carnitine C0 22 20 161.9→84.6 C0-D9 170.9→84.6 1.73 to 2.03 
Acetylcarnitine C2 22 20 203.9→84.6 C2-D3 206.9→84.6 1.57 to 1.87 
Propionylcarnitine C3 22 20 217.9→84.6 C3-D3 220.9→84.6 1.43 to 1.73 
Butyrylcarnitine C4 22 21 231.9→84.6 C4-D3 235.0→84.6 1.31 to 1.61 
Valerylcarnitine C5 22 23 246.0→84.6 C5-D9 255.1→84.6 1.21 to 1.51 
Hexanoylcarnitine C6 22 23 260.0→84.6 C8-D3 291.1→84.6 1.10 to 1.40 
Octanoylcarnitine C8 22 23 288.1→84.6 C8-D3 291.1→84.6 0.97 to 1.27 
Decanoylcarnitine C10 22 28 316.1→84.6 C8-D3 291.1→84.6 0.80 to 1.10 
Lauroylcarnitine C12 22 28 344.1→84.6 C14-D9 381.2→84.6 0.63 to 1.01 
Myristoylcarnitine C14 22 28 372.1→84.6 C14-D9 381.2→84.6 0.63 to 1.01 
Palmitoylcarnitine C16 22 28 400.2→84.6 C16-D3 403.2→84.6 0.00 to 0.95 
Stearoylcarnitine C18 22 28 428.2→84.6 C16-D3 403.2→84.6 0.00 to 0.95 
 
4.2.3  UV/NIR-instrumentation  
Dried blood spot samples were analyzed with a QE65000 Scientific-Grade Spectrometer 
and deuterium tungsten halogen light source from Ocean Optics (Dunedin, FL). Reflectance 
measurements were made with a R400-7-VIS/NIR reflectance probe, Ocean Optics.  Data was 
collected from 200-1000 nm using a 6 msec integration time and a boxcar smooth setting of 2.  
The reflectance probe was held in position using a gripper mounted to a ring stand. A picture of 
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the reflectance probe apparatus is shown in Figure 4.1. In order to analyze the samples in 
reflectance mode the background of the detector and the sample must be analyzed.  First the 
background from the detector is accounted for by taking a reference “dark” sample in which 
the detector was blocked from all light.  Next a reference “light” sample is collected, for this we 
used a blank Whatman 903 filter paper card.  This was done in order to account for the 
inherent background peaks present in the Whatman 903 filter paper that absorb UV/NIR light.  
Using the paper as a reference allows for these peaks to be subtracted from the data collected 
for reflectance, absorbance and light scattering measurements. Also the ambient light was 
reduced by turning off all overhead lights to eliminate background light from interfering with 
the analysis.   An alternative approach to block out all light would be to move the black collar 
around the end of the probe to be flush with the dried blood spot.  However, using the collar to 
block all light also makes it difficut to see where you are taking measurements, so in order to 
make sure we sampled appropiately we elected not to use the collar.    
For probe height optimization an adjustable stage was placed below the probe to adjust 
the height of the probe above the sample.  Following the optimization experiment the 
adjustable stage was removed and the probe was fixed at the optimized distance from the base 
in order to make optical measurements more consistent.   
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Legend: A: Reflectance probe positioned above dried blood spot, B: Expanded view of reflectance probe 
set-up showing ring stand holder.  
Figure 4.1: UV-reflectance fiber optic probe setup, showing how the probe is held in position 
above dried blood spot   
 
 
4.2.4  Preparation of dried blood spots 
Potassium EDTA human whole blood was used to prepare samples at 25%, 35%, 45%, 
55%, 65% and 75% hematocrit by first measuring the hematocrit by centrifuging the samples at 
3500 rpm for 20 minutes and measuring the volume of red blood cells.  The hematocrit was 
adjusted by adding or removing serum.  The red blood cells were re-suspended by gentle 
mixing.  For quantitative purposes, individually prepared reference standards containing 
acylcarnitines (Carnitine, C2, C3, C4, C5, C6, C8, C10, C12, C14, C16 and C18) were fortified into 
the whole blood at approximately ten times the endogenous level. After thoroughly mixing the 
samples, 50 µL of unfortified and fortified whole blood samples at the various levels of 
hematocrit were spotted on three different lots of Whatman 903 Protein Saver newborn 
 111 
screening cards.  For DMPK filter paper cards only 15 µL of blood was spotted on filter paper 
due to cards are for smaller sample volumes.  In addition, 10 µL, 25 µL and 100 µL of the same 
samples were spotted on separate Whatman 903 filter paper cards.  All samples were allowed 
to thoroughly dry at room temperature and then stored at 0-5 oC until analyzed.  Figure 4.2 is a 
picture of the dried blood spots from 25% hematocrit to 75% hematocrit after drying. There are 
some distinct differences observed in the dried blood spots at the various hematocrit levels.  
Samples prepared at 25% and 35% hematocrit appear to have a second lighter ring that diffuses 
out farther from the center.  As the hematocrit level increases to about 45% this ring becomes 
less apparent.  Samples prepared at 65 to 75% hematocrit appear much darker in color and do 
not fill the entire spot with 50 µL of blood.   
 
 
Figure 4.2: Dried blood spots prepared at various levels of hematocrit, 50 µL of blood was 
spotted on Whatman 903 filter paper 
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4.3  Results and Discussion 
4.3.1  UV reflectance of dried blood spots 
For our initial investigations we collected absorbance, reflectance and light scattering 
data when the probe was positioned perpendicular to the dried blood spot samples. There did 
appear to be some similarities between reflectance and absorbance spectra, however light 
scattering alone did not provide identifiable differences between samples at different levels of 
hematocrit. The absorbance spectra appears to be the inverse of the reflectance spectra.  Since 
we are measuring diffuse reflectance which is a measure of both light scattering and 
absorbance, we decided to collect the data in reflectance mode; however absorbance could 
provide similar results.  
4.3.2  Probe height optimization  
Since reflectance is related to the intensity of the light we first optimized the probe 
position above the sample.  The probe height was optimized by measuring the reflectance from 
210 to 1000 nm for 25%, 55% and 75% hematocrit dried blood spot samples.  The position of 
the probe was adjusted from 0 mm to 10 mm from the surface of the spot in 1 mm increments 
by raising and lowering an adjustable stage.  Triplicate analysis of each sample was performed 
at different locations for each hematocrit at 25%, 55% and 75%.  Reflectance measurements 
were evaluated for several different wavelengths from 200 to 1000 nm.  Wavelengths below 
800 nm did show provide a relationship between % hematocrit and reflectance, however 
wavelengths above 800 nm all had a similar correlation but the slope was larger.  A larger slope 
provides improved sensitivity for this analysis allowing for better discrimination between 
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samples.  For this experiment the responses were plotted for 980 nm to show the effect of 
probe position above the spot related to reflectance for several hematocrit levels, Figure 4.3.  
 
 
Legend: Error bars represent 1 standard deviation 
Figure 4.3: Optimization of probe height above dried blood spot for reflectance 
measurements at 980 nm, evaluated with samples prepared at 25%, 55% and 75% 
hematocrit, samples analyzed in triplicate   
 
From our data it was apparent that 3-4 mm above the surface of the probe provided the 
highest relative intensity for each hematocrit level.  At positions lower than 3 mm the mean  
reflectance values for 55% and 75% hematocrit were not significantly different using a t-test,  
p = 0.396.  Measurements above 4 mm had less intensity which was probably due to the 
diffusion of light created by moving the probe farther away from the samples.  For this reason 
we choose 3-4 mm to evaluate the relationship between percent reflectance and hematocrit. 
Figure 4.4 shows a plot for the percent reflectance versus hematocrit plotted for 3 mm and 4 
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mm. The correlation coefficient was calculated both 3 mm and 4 mm using linear regression in 
Excel and determined to be 0.983 and the slope of both lines were -0.625 ±0.04. Although there 
was no apparent difference between the two heights, either position could be used for this 
analysis. We decided to use a probe height of 4 mm for all additional experiments. 
 
Legend: Error bars represent 1 standard deviation  
Figure 4.4: Percent reflectance at 980 nm plotted for probe positioned at 3 mm and 4 mm 
above the dried blood spot for samples prepared at 25%, 55% and 75% hematocrit, samples 
analyzed in triplicate 
4.3.3  UV reflectance analysis of control samples  
Reflectance measurements were made for control samples prepared at 25%, 35%, 45%, 55%, 
65% and 75% hematocrit.  Samples were analyzed in triplicate at different positions on a dried 
blood spot. In addition three different lots of Whatman 903 filter paper and one lot of DMPK 
filter paper were analyzed.  UV spectra from 200 nm to 1000 nm was collected for each sample 
to generate UV reflectance spectra, Figure 4.5.  The reflectance measurements for samples with 
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different hematocrits do have some distinct features as referenced by Serebrennikova 
(Serebrennikova, Smith, Huffman, Leparc, & García-Rubio, 2008).  Also, there were two distinct 
bands at 540 nm and 570 nm which have been previously reported as characteristic 
hemoglobin bands (Yu et al., 2008; Zijlstra et al., 1991).  The region above 800 nm has few 
distinct features and provides a relationship between hematocrit and reflectance.   
 
Legend: UV reflectance measurements for dried blood spot samples at various hematocrit levels as 
indicated. Blank is a blank newborn screening card. Distinct hemoglobin bands can be seen at 540 nm 
and 570 nm. 
Figure 4.5: UV/NIR reflectance spectra for dried blood spots prepared at various levels of 
hematocrit and an absorbance spectra for a blank Whatman 903 filter paper sample 
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Data analysis of the UV reflectance spectra was performed by extracting percent 
reflectance at different wavelengths and plotting the signal response versus percent 
hematocrit.  Several wavelengths show a linear correlation between percent hematocrit and 
hemoglobin; however 980 nm showed the best correlation and had the largest slope.  Since the 
slope is the sensitivity of the analysis the linear relationship with the largest slope was chosen.  
Dried blood spots prepared at various levels of hematocrit were evaluated on two additional 
lots of Whatman 903 filter paper and on lot of DMPK filter paper cards.  Acceptable, linear 
relationships with correlation coefficients greater than 0.9939 were observed for each set of 
samples, however there did appear to be slight differences between the reflectance response 
for samples prepare with DMPK filter paper and the Whatman 903 filter paper (Figure 4.6).  
This difference may be related to the volume of blood spotted on the DMPK filter paper cards 
was only 15 µL , where the volume of blood spotted on the Whatman 903 filter paper cards was 
50 µL.  It has been previously reported that volume of blood spotted on filter paper affects the 
volume of sample analyzed from a 6 mm punch (Mei et al., 2001).  
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Legend: Three different lots of Whatman 903 filter paper (Squares, Diamonds and Triangles) 
One lot of DMPK filter paper (Circles). Error bars represent 1 standard deviation 
Figure 4.6: Plot of reflectance measurement at 980 nm versus hematocrit for control samples 
prepared at different levels of hematocrit on three different lots of Whatman 903 filter paper 
and one lot of DMPK filter paper, samples analyzed in triplicate each measurement made at a 
different location on the dried blood spot 
 
The average response for each hematocrit level on the three different lots of Whatman 
903 filter paper was used for our model.  A linear model was achieved between percent 
reflectance and hematocrit with an overall correlation coefficient 0.9933.  This model was used 
to calculate the percent hematocrit for the donor samples at low, normal and high hematocrit 
levels. 
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Legend: Error bars represent 1 standard deviation from the average of three different lots of 
Whatman 903 filter papers. 
Figure 4.7: Plot of the average reflectance at 980 nm versus hematocrit for control samples 
prepared at different levels of hematocrit on three different lots of Whatman 903 filter 
paper, each filter paper lot was analyzed in triplicate 
4.3.4 Evaluation of sample volume on reflectance 
 The volume of blood spotted has also been shown to affect the sample size (Mei et al., 
2001).  When spotting small volumes (15 µL) of blood the percent hematocrit has been shown 
to have less effect on sample size (Denniff & Spooner, 2010).  However the sample volume can 
increase by as much as 15% between 25 µL of blood spotted and 125 µL of blood spotted on 
filter paper (Mei et al., 2001).  Therefore we decided to investigate the reflectance 
measurement for samples that were prepared with different volumes of blood.  Samples 
prepared with 10 µL, 25 µL 50 µL and 100 µL at 35%, 55% and 65% hematocrit were analyzed 
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using UV reflectance at 980 nm.  Samples were analyzed in triplicate for each volume and 
hematocrit level at various positions on dried blood spots, results are shown in Figure 4.8. 
 
 
Legend: Error bars represent 1 standard deviation. 
Figure 4.8 Plot of blood volume spotted on Whatman 903 filter paper cards versus reflectance 
measurements at 980 nm for blood containing 35%, 55% and 65% hematocrit, dried blood 
spots were prepared by spotting 10 µL, 25 µL, 50 µL and 100 µL of blood on filter paper, 
samples were analyzed in triplicate 
 
 It is apparent from Figure 4.8 that as the volume of sample spotted on the filter paper 
increases there is a decrease in the percent reflectance.  Also the decrease in reflectance is not 
consistent from 35% hematocrit to 65% hematocrit, as shown by the slope of the lines -0.033 
and –0.066 respectively. Samples prepared with 65% hematocrit showed the largest decrease 
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in reflectance as the volume of blood spotted increased from 10 µL to 100 µL.  Using just 
reflectance alone, it would not be possible to distinguish between a 10 µL sample with a 65% 
hematocrit spotted and 100 µL sample with a 55% hematocrit.  However, 50-100 µL of blood 
spotted have differences between 35%, 55% and 65%. The manufacture indicates that the 
amount of blood that will fill the circular region on a dried blood spot is between 75 to 100 µL 
of blood.  
4.3.5 Evaluation of hematocrit in donor samples 
In order to evaluate the accuracy of our model donor samples prepared at low, normal 
and high hematocrits were evaluated with UV reflectance.  Each dried blood spot was analyzed 
in triplicate at different positions to test the intra spot variability.  Reflectance data was 
collected for each sample from 200 nm to 1000 nm for each sample.  The response at 980 nm 
was used to back calculate the hematocrit level using our model, shown in Figure 4.7.  Results 
from this experiment are presented in Table 4.2, along with the predetermined hematocrit 
levels and the percent difference from our measured value.  The overall percent hematocrit 
determined using UV reflectance was within + 11% of the measured value.  In addition, the 
overall percent relative standard deviations for three replicate measurements at three 
hematocrit levels were within 11%.   
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Table 4.2: Determination of hematocrit for donor samples using reflectance at 980 nm.  
Low Level Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 
Rep 1 32 35 39 24 30 24 
Rep 2 28 33 39 25 32 24 
Rep 3 32 34 42 23 34 24 
Mean 31 34 40 24 32 24 
S.D. 2 1 2 1 2 0 
%RSD 7% 4% 5% 5% 6% 1% 
Measured Hematocrit 29 34 36 25 32 27 
% Difference from Measured 6% 0% 11% -6% 0% -11% 
       
Normal Level Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 
Rep 1 49 52 50 39 47 37 
Rep 2 49 49 48 38 45 38 
Rep 3 48 54 52 41 50 35 
Mean 49 51 50 39 47 36 
S.D. 0 2 2 2 2 1 
%RSD 1% 5% 4% 4% 5% 4% 
Measured % Hematocrit 46 51 50 38 48 41 
% Difference from Measured 6% 1% 0% 4% -2% -11% 
       
High Level Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 
Rep 1 76 64 71 65 58 69 
Rep 2 69 73 73 70 68 67 
Rep 3 64 79 68 64 59 61 
Mean 69 72 70 66 62 66 
S.D. 6 8 3 3 6 4 
%RSD 9% 11% 4% 5% 9% 6% 
Measured % Hematocrit 66 71 71 68 67 68 
% Difference from Measured 5% 0% -1% -3% -8% -4% 
 
4.4  Quantitative analysis  
4.4.1  Quantitative analysis of control samples to determine sample volume 
Quantitative analysis of the dried blood spots was used to evaluate the relationship 
between sample volume and hematocrit.  There have been others that have evaluated this 
relationship for selected pharmaceutical compounds and for amino acids and acylcarnitines for 
 122 
dried blood spots at various hematocrit levels.  We are reporting data for a wider range of 
hematocrit than was previously reported. And it was necessary to establish measurements 
based on our samples to show the relationship between UV reflectance and sample volume. 
For this experiment, a 3.0 mm punch from dried blood spots using samples prepared 
with 50 µL of whole blood spotted on Whatman 903 filter paper.  Samples were extracted in 
0.100 mL of a mixture of 90:10 acetonitrile/water with 10 mM ammonium formate and  
analyzed by LC/MS/MS for acylcarnitines using a HILIC Amide (2.1 x 50 mm, 1.7 µm) column at a 
flow rate of 0.3 mL/minute.  Compounds were eluted using a gradient elution form 95% B to 
55% B over 3 minutes with 90:10 acetonitrile/10 mM ammonium acetate for mobile phase B 
and 0.1% formic acid in water for mobile phase A.  Multiple reaction monitoring (MRM) of 12 
acylcarnitines was performed on a Waters Premier mass spectrometer with positive 
electrospray ionization, with optimized MRMs shown in Table 4.1.  Samples were quantified 
using an external calibration curve prepared in 90:10 Acetonitrile/ 10mM ammonium formate 
containing Carnitine, C2, C3, C4, C5, C6, C8, C10, C12, C14, C16, C18. 
Dried blood spot samples from each of the three lots of Whatman 903 filter paper were 
analyzed in triplicate at each hematocrit level from 25% to 75%.  Back calculated values of each 
analyte were determined using the external calibration curve.  The volume of the sample was 
determined based on the fortified level and back calculated concentration using Equation 4.1: 
Equation 4.1: Calculation for sample volume from an extracted dried blood spot sample 
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Sample volume was calculated for each analyte Carnitine, C2, C3, C4, C5, C6, C8, C10, C12, C14, 
C16  and C18, since it was previously reported that some analytes appear to have a 
chromatographic effect on the filter paper cards.  Although there were some differences 
observed in the sample volume when calculated using different analytes the overall differences 
were less than 10%.  The volume for each hematocrit level was calculated by averaging the 
results obtained from all the analytes.  The overall % relative standard deviations were less than 
10%.  Results for the average volume verses hematocrit determined on the three lots of 
Whatman 903 filter paper are shown in Figure 4.9.   
 
Legend: Error bars represent 1 standard deviation. 
Figure 4.9: Plot of sample volume versus hematocrit for dried blood spots analyzed from a 3.0 
mm punch, sample volume calculated using quantitative analysis of Carnitine, C2, C3, C4, C5, 
C6, C8, C10, C14, C16, C18 for 3 different lots of Whatman 903 filter paper, each data point 
represents the average volume calculated using the all the analytes and each sample was 
analyzed in triplicate 
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It was apparent from our results that as the percent hematocrit increases there is an 
increase in sample volume.  There is approximately a 55% increase in sample volume from 25% 
hematocrit to 75% hematocrit.  The three different lots of Whatman 903 filter paper cards 
showed consistent results for each of the different hematocrit levels.  The overall average from 
the three different lots of Whatman 903 filter paper were used to determine the average 
volume for each hematocrit level. A linear correlation with a slope of 2.42(+ 0.14), a y-intercept 
of 1.58 (+0.07) and a coefficient of determination (R2) of 0.9860 was obtained, Figure 4.10.  This 
curve was used to determine sample volume of the donor samples based on the response from 
the reflectance measurements. 
 
Figure 4.10: Plot of the average volume from a dried blood spot calculated from quantitative 
analysis of Carnitine, C2, C3, C4, C5, C6, C8, C10, C14, C16, C18 from a 3 mm punch using 3 
different lots Whatman 903 filter paper versus hematocrit from 25% to 75%.  
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4.4.2  Quantitative analysis of donor samples 
Eighteen donor samples at high, normal and low hematocrit levels were extracted using 
the same conditions as described earlier.  Back calculated concentrations were determined for 
each acylcarnitne C0, C2, C3, C4, C5, C6, C8, C10, C12, C14, C16 and C18 using response ratios 
with labeled internal standards.  Analyte concentrations were first calculated using assuming 
the sample volume extracted was 3.1 µL from a 3 mm punch. Table 4.3 shows the calculated 
accuracy for each analyte based on the known fortified concentration. The average accuracy for 
individual acylcarnitines in the low hematocrit samples ranged from 67% to 82% for an overall 
accuracy of 76% ± 4%.  The average accuracy for individual acylcarnitines in the high hematocrit 
samples ranged from 94% to 136% for an overall accuracy of 110% ± 10%. 
Next the same data was recalculated with the appropriate volume using the hematocrit 
determined from the reflectance measurements reported in Table 4.2.   Sample volumes were 
calculated for the hematocrit level in each sample using the equation in Figure 4.10.  Using the 
volume correction the accuracy was determined Table 4.4 shows the calculated accuracy for 
each analyte based on the known fortified concentration. The average accuracy for individual 
acylcarnitines in the low hematocrit samples ranged from 97% to 114% for an overall accuracy 
of 103% ± 5%.  The average accuracy for individual acylcarnitines in the high hematocrit 
samples ranged from 81% to 115% for an overall accuracy of 98% ± 8%.   
Overall there was a negative bias of 24% for low hematocrit samples when volume of 
the excised samples was not corrected for volume based on hematocrit.  There was a slight 
positive bias of 10% observed for samples at high hematocrit when the excised sample was not 
corrected for volume based on hematocrit.  However when sample volumes were corrected for 
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hematocrit that was determined by using our reflectance technique the overall bias was 
reduced to less than 3%. In addition correcting for sample volume improved the precision of 
the analysis by reducing the percent relative standard deviations from 18.7% to 11.7%.    
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Table 4.3: Calculation of percent accuracy for acylcarnitines in 6 donor samples at low, 
normal and high hematocrit. Samples not corrected for volume. 
  Donor Samples at Low Level Hematocrit  
Donor C0 C2 C3 C4 C5 C6 C8 C10 C12 C14 C16 C18 
1 78% 65% 69% 79% 77% 75% 78% 75% 74% 83% 76% 77% 
2 81% 74% 75% 80% 78% 76% 79% 76% 76% 80% 79% 79% 
3 89% 81% 83% 86% 85% 84% 89% 82% 90% 91% 89% 86% 
4 66% 65% 67% 70% 68% 64% 68% 70% 73% 75% 70% 73% 
5 81% 72% 79% 81% 80% 73% 81% 76% 79% 85% 82% 83% 
6 67% 44% 64% 74% 72% 69% 73% 72% 73% 78% 72% 72% 
Mean 77% 67% 73% 78% 77% 73% 78% 75% 78% 82% 78% 78% 
S.D. 8.8% 12.5% 7.5% 5.6% 5.9% 6.6% 7.2% 4.2% 6.6% 5.6% 6.8% 5.5% 
%RSD 11.5% 18.7% 10.3% 7.1% 7.7% 9.0% 9.2% 5.5% 8.6% 6.8% 8.7% 7.0% 
Overall 76% 
           
               Donor Samples at Normal Level Hematocrit  
  C0 C2 C3 C4 C5 C6 C8 C10 C12 C14 C16 C18 
1 88% 95% 93% 95% 90% 87% 90% 83% 87% 94% 86% 86% 
2 84% 98% 89% 85% 84% 81% 84% 74% 82% 83% 84% 85% 
3 93% 103% 99% 93% 92% 92% 97% 87% 98% 96% 98% 95% 
4 75% 87% 83% 82% 76% 76% 83% 79% 83% 85% 82% 81% 
5 87% 98% 95% 96% 91% 90% 92% 85% 99% 96% 95% 93% 
6 68% 68% 74% 81% 78% 73% 77% 76% 80% 82% 76% 76% 
Mean 82% 91% 89% 89% 85% 83% 87% 81% 88% 89% 87% 86% 
S.D. 9.4% 12.7% 8.9% 6.9% 6.9% 8.0% 7.2% 5.2% 8.3% 6.7% 8.1% 7.1% 
%RSD 11.4% 13.9% 10.1% 7.7% 8.1% 9.6% 8.3% 6.4% 9.4% 7.5% 9.3% 8.2% 
Overall 87% 
           
               Donor Samples at High Level Hematocrit  
  C0 C2 C3 C4 C5 C6 C8 C10 C12 C14 C16 C18 
1 94% 142% 115% 109% 108% 110% 113% 102% 118% 114% 108% 106% 
2 96% 138% 114% 108% 107% 100% 106% 95% 108% 101% 101% 98% 
3 101% 141% 121% 114% 110% 107% 115% 108% 118% 113% 110% 103% 
4 95% 143% 119% 113% 112% 105% 114% 100% 117% 111% 116% 111% 
5 92% 128% 120% 122% 112% 105% 112% 104% 109% 110% 102% 97% 
6 86% 125% 113% 120% 115% 111% 110% 98% 106% 99% 99% 95% 
Mean 94% 136% 117% 114% 111% 107% 112% 101% 113% 108% 106% 102% 
S.D. 4.8% 7.8% 3.5% 5.5% 2.8% 3.8% 3.3% 4.4% 5.5% 6.2% 6.8% 6.4% 
%RSD 5.2% 5.7% 3.0% 4.8% 2.5% 3.6% 2.9% 4.3% 4.9% 5.7% 6.4% 6.3% 
Overall 110% 
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Table 4.4:  Calculation of percent accuracy for acylcarnitines in 6 donor samples at low, 
normal and high hematocrit. Samples corrected for volume using reflectance measurements 
  Donor Samples at Low Level Hematocrit  
 Donor  C0 C2 C3 C4 C5 C6 C8 C10 C12 C14 C16 C18 
1 111% 97% 92% 104% 101% 98% 103% 98% 97% 108% 102% 104% 
2 111% 107% 96% 102% 98% 96% 100% 96% 97% 101% 102% 104% 
3 113% 106% 99% 102% 101% 99% 105% 97% 106% 107% 106% 103% 
4 112% 117% 100% 102% 98% 93% 99% 101% 105% 108% 108% 111% 
5 119% 111% 105% 106% 104% 95% 105% 98% 103% 110% 110% 111% 
6 118% 83% 94% 107% 103% 99% 105% 104% 104% 112% 109% 109% 
Mean 114% 104% 98% 104% 101% 97% 103% 99% 102% 108% 106% 107% 
S.D. 3.6% 11.7% 4.7% 2.2% 2.4% 2.4% 2.9% 2.8% 4.1% 3.7% 3.4% 3.9% 
%RSD 3.1% 11.3% 4.8% 2.1% 2.3% 2.5% 2.8% 2.9% 4.0% 3.4% 3.2% 3.6% 
Overall 103% 
             
  Donor Samples at Normal Level Hematocrit  
 Donor C0 C2 C3 C4 C5 C6 C8 C10 C12 C14 C16 C18 
1 94% 102% 101% 102% 96% 94% 97% 89% 94% 101% 93% 93% 
2 89% 105% 93% 90% 89% 84% 88% 78% 86% 87% 88% 89% 
3 102% 114% 105% 99% 98% 98% 103% 93% 104% 102% 105% 102% 
4 115% 97% 99% 95% 94% 97% 121% 105% 108% 106% 108% 102% 
5 100% 115% 105% 106% 100% 99% 101% 94% 108% 105% 105% 104% 
6 94% 98% 93% 100% 96% 90% 94% 94% 98% 101% 97% 98% 
Mean 99% 105% 99% 99% 96% 94% 101% 92% 100% 100% 99% 98% 
S.D. 8.8% 7.7% 5.3% 5.7% 3.9% 5.7% 11.1% 8.8% 8.8% 6.9% 7.8% 5.6% 
%RSD 8.9% 7.3% 5.4% 5.8% 4.1% 6.0% 11.0% 9.5% 8.8% 6.8% 7.9% 5.7% 
Overall 98% 
             
  Donor Samples at High Level Hematocrit  
 Donor C0 C2 C3 C4 C5 C6 C8 C10 C12 C14 C16 C18 
1 77% 111% 101% 97% 97% 98% 101% 91% 105% 102% 95% 92% 
2 79% 112% 99% 94% 94% 88% 93% 83% 94% 89% 87% 84% 
3 84% 115% 106% 101% 97% 95% 102% 95% 105% 100% 96% 90% 
4 83% 123% 108% 104% 102% 96% 104% 91% 107% 102% 105% 100% 
5 85% 118% 114% 116% 107% 101% 107% 99% 104% 105% 97% 92% 
6 76% 108% 103% 110% 106% 103% 102% 91% 98% 91% 90% 86% 
Mean 81% 115% 105% 104% 100% 97% 102% 92% 102% 98% 95% 91% 
S.D. 4.0% 5.5% 5.5% 8.3% 5.4% 5.1% 4.9% 5.2% 4.8% 6.4% 6.0% 5.8% 
%RSD 4.9% 4.8% 5.3% 8.0% 5.4% 5.3% 4.8% 5.7% 4.7% 6.6% 6.4% 6.3% 
Overall 98%            
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4.5  Conclusions 
We have developed a novel approach that allows for the determination of hematocrit 
directly on dried blood spots using reflectance.  In addition, we have shown that the sample 
volume is dependent on the percent hematocrit and can be used to correct for sample volume.  
Donor samples at various hematocrits were used to test both models and demonstrated 
acceptable precision and improved accuracy over the standard technique which assumes that 
all samples are 3 µL.  The ability to predetermine the hematocrit directly on dried blood spots 
using UV reflectance can be used to correct for sample volume, improving the accuracy of this 
sample collection technique. Correcting for volume greatly improves the accuracy of analysis 
and the reflectance format used allows for direct automatable volume corrections on the card 
without the need for off line procedures to test whole blood. 
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CHAPTER 5 
 
SUMMARY AND OVERALL CONCLUSIONS 
 
 According to the CDC there are over 4 million children born every year in the United 
States.  It is a state mandated requirement that all of these children be tested for inheritable 
metabolism disorders, endocrinopathies, hemoglobinopathies and genetic disorders.  Dried 
blood spot analysis has been pivotal to newborn screening, since it is an extremely cost 
effective way of collecting, shipping and storing samples.  It has been more than 50 years since 
dried blood spots were developed for the analysis of PKU by Robert Guthrie and newborn 
screening has grown to test for more than 40 metabolism disorders.  Although this testing 
program has been claimed to be one of the most successful public health programs, there is an 
increasing need to further improve this testing.  Newborn screening allows for the quick 
identification of disorders; however the current methods are not fully quantitative and often 
require second-tier testing or follow-up testing by an independent laboratory to confirm a 
disorder.  This adds additional time to diagnosis and an increase cost to state newborn 
screening laboratories and an increase cost to health care.  By providing newborn screening 
laboratories with new techniques and new technologies we can further improve the accuracy of 
analysis, reduce costs and shorten the time to diagnosis.  This is why we decided to investigate 
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new approaches to dried blood spot analysis using automation and high resolution 
chromatography.  
The first chapter of this dissertation covers the background to newborn screening dried 
blood spot analysis for the identification of metabolism disorders.  Although current flow 
injection approach used by newborn screening laboratories does provide a rapid screening 
technique there are several potential issues with this method.  In order to address some of 
these issues we developed a high resolution liquid chromatographic separation that could be 
conducted in approximately the same time as the current screening method. Chapter 1, also 
provides a review of current techniques available for direct analysis of dried blood spots which 
have been developed since the start of our research. Several of these devices have been 
automated to increase efficiencies in dried blood spot analysis and minimize sample handling 
requirements ultimately reducing costs and improving laboratory efficiencies. We were the first 
to publish a device that allowed for direct sampling of newborn screening cards without the 
need for punching disks from dried blood spots. Chapter 1, also reviews recent literature that 
has investigated the affect hematocrit has on sample volume in dried blood spot analysis.  It has 
been reported that hematocrit has the largest effect of sample size for dried blood spot analysis 
compared to volume spotted on filter paper and punch location (Mei et al., 2001).  Although, 
there is some controversy as to how dramatic this effect is for normal hematocrit levels there 
does appear to be a significant bias of analyte concentration in samples with low and high 
hematocrit.   
In chapter 2, we provide a full description of our high resolution chromatographic 
separation along with data supporting the method validation.  We showed the ability to 
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separate key isobars that are diagnostic for different metabolism disorders, which is not 
possible with the current flow injection approach.  We also address several key issues not 
previously addressed in newborn screening such as matrix effects and quantification errors 
associated with response factors.  A comparison between the current newborn screening 
method and our modified screening method using high resolution chromatography is outlined 
in table 5.1. 
  Table 5.1: Comparison between the current newborn screening method used by most state 
laboratories and our modified method using a high resolution chromatographic separation 
Current newborn screening method Modified screening method with  chromatographic separation 
Labor intensive extraction: 
1. Samples must be transferred twice 
2. Requires hazardous derivatization 
3. Evaporation 
 
Fewer extraction steps: 
1. Samples transferred once 
2. No derivatization 
3. No evaporation 
Not fully quantitative: 
1. Samples quantified based on single 
point response factors with labeled 
internal standards 
2. Matrix effects could cause errors in 
quantification 
 
Improved quantification: 
1. Samples quantified using internal 
calibration curve encompassing a 
range above and below cut-off value  
2. Minimizes matrix effects by 
chromatographically resolving 
interferences 
 
Poor selectivity and sensitivity: 
1. No Chromatographic separation of 
isobars, requires additional testing for 
differential diagnosis of certain 
disorders 
2. Precursor ion scan and neutral loss 
scan used for analysis reduces 
sensitivity 
Improved selectivity and sensitivity: 
1.  Chromatographically separates key 
isomers allowing for differential 
diagnosis of multiple disorders 
2. Scheduled MRMs are used for analysis 
improving the analyte sensitivity  
 
Chapter 3, provides a practical application using our in-line desorption device with a 
chromatographic separation.  A method was developed and validated for quantification of 
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leucine and isoleucine which are markers for MSUD.  Our approach allowed for the direct 
analysis of dried blood spots without the need for any off-line sample processing.  Our 
chromatographic separation is capable of resolving leucine, isoleucine and hydroxylproline, and 
could be used as a rapid second tier test for MSUD.  This was the first published paper that 
incorporated a flow through device with a high resolution chromatographic separation. 
Finally we addressed the major concern in dried blood spot analysis which is the 
influence of hematocrit on sample volume.  In the fourth chapter we evaluated the ability to 
correct for sample volume using a hematocrit determined by direct analysis of the dried blood 
spot with UV reflectance at 980nm.  Our technique provides a relationship between reflectance 
and hematocrit that can be used prior to sample analysis to correct sample volume.  We 
validated our reflectance model to determine hematocrit through the analysis of donor 
samples prepared at various hematocrit levels.  We also showed that sample volume is 
dependent on hematocrit and is consistent from lot to lot of Whatman 903 filter paper cards.  
Using both the reflectance measurement and the quantitative analysis of samples we could 
relate the reflectance measurement to sample volume. To validate our technique donor 
samples were analyzed at various levels of hematocrit and quantified with and without 
correcting for sample volume.  Correcting for sample volume showed a dramatic improvement 
in accuracy at low and high hematocrit levels. 
Overall we addressed several of the current issues associated with newborn screening  
dried blood spot analysis.  We addressed the lack of specificity in newborn screening by adding 
a high resolution chromatographic separation that could be conducted in approximately the 
same time as the flow injection analysis.  We provided a direct analysis technique that could be 
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automated increasing laboratory efficiencies which minimizes sample handling requirements.  
Finally, we addressed a major concern which was how to correct for differences in hematocrit 
by applying UV-NIR reflectance as a means to directly analyze dried blood spots to determine 
hematocrit and relating this to sample volume. The device that we evaluated was a fiber optic 
probe that allowed for direct measurements to be made to the dried blood spot.  The simplicity 
of this device and the use of fiber optics would allow for it to be easily integrated by newborn 
screening laboratories.  These improvements that we have investigated could dramatically 
improve the efficiencies and accuracy of newborn screening dried blood spot analysis. 
Although our research does provide significant improvements to the newborn screening 
methodology we were not able to test our methodologies with incurred samples from real 
newborns.  This is due to the limited availability of newborn screening samples and potential 
controversies associated with analysis of samples from other laboratories.  We believe the next 
step to this research would be to apply our methods in parallel with the current methods using 
incurred samples from newborns.  Future work could also investigate the ability to add 
additional markers to the high resolution chromatographic separation.  This would allow for 
more accurate diagnosis of disorders that have more selective markers available for 
identification such as methylmalonic acid for methylmalonic acidemia (MMA).  Also, several in-
line desorption devices are now commercially available and could be investigated for newborn 
screening dried blood spot analysis with or without chromatographic separation for 
identification of metabolism disorders.  This would dramatically decrease the workloads of 
newborn screening reducing costs and improving efficiencies.  Finally the use of NIR reflectance 
analysis should be evaluated with incurred samples from newborns to evaluate the potential to 
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evaluate hematocrit on dried blood spots.  Our approach was acceptable under controlled 
conditions; however it should be further evaluated with real samples spotted as they would be 
by health care providers. 
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